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ASTRACT 
 
LISA HEIMBACH: Mast cell activation and signaling in the autoimmune disease bullous 
pemphigoid 
(Under the direction of Dr. Zhi Liu) 
 
 
 Bullous pemphigoid (BP) is an autoimmune skin blistering disorder primarily 
observed in the elderly.  Autoantibodies directed against the hemidesmosomal protein BP180 
trigger a pathological inflammatory response that causes separation of the epidermis from the 
underlying dermis.  Complement, mast cells (MCs), and polymorphonuclear neutrophils 
(PMNs) are required for disease in experimental BP, an animal model that closely mimics the 
clinical, immunological and histological features of human BP.  In this work, we investigated 
MC activation and signaling in experimental BP. 
 MC degranulation occurs downstream of complement activation and the generation of 
complement component 5a (C5a) in experimental BP.  We determined that C5a binds to the 
C5a receptor (C5aR) on MCs in neonatal mice given disease-inducing antibodies.  C5a-C5aR 
interaction significantly increases phosphorylation of the intracellular signaling protein p38 
mitogen-activated protein kinase (p38MAPK).  Pharmacologically blocking p38MAPK 
activation protected mice from MC degranulation and clinical disease.   Taken together, we 
demonstrated that the binding of C5a to C5aR on MCs activates the p38MAPK signaling 
pathway and leads to MC degranulation and skin blistering. 
Upon degranulation, MCs release bioactive compounds from their secretory granules, 
including tumor necrosis factor-alpha (TNF-α).  Here, we report that MC-derived TNF-α is 
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required for disease in experimental BP.  Mice lacking TNF-α globally or in MCs alone fail 
to recruit sufficient numbers of PMNs to the skin and do not develop clinical blisters 
following injection with pathogenic anti-BP180 antibodies.  C5aR-deficient mice are 
protected from blistering and do not exhibit elevated TNF-α levels or MC degranulation.  
TNF-α receptor 1 (TNFR1) expression on MCs is required for development of experimental 
BP, suggesting that TNF-α acts in an autocrine fashion on MCs. 
The findings described in this dissertation refine our understanding of the 
mechanisms of MC degranulation in experimental BP.  MCs are activated by the binding of 
C5a to C5aR.  C5a-C5aR interaction leads to activation of p38MAPK and MC degranulation.  
MC degranulation releases TNF-α, and TNF-α acts in an autocrine manner on MC TNFR1 to 
promote disease development.  In addition to providing insight into the pathogenesis of BP, 
our data also suggests that C5a, p38MAPK, and TNF-α may be promising therapeutic targets 
for treatment of human disease.  
 
 
 
 
  
v 
 
 
This dissertation is dedicated to my husband, Matthew, and my parents, Mike and Kim.  
Thank you for your love and support.  
vi 
 
 
ACKNOWLEDGEMENTS 
I would like to thank my advisor, Dr. Zhi Liu, for his support and guidance 
throughout my graduate school career.  From him, I have learned to be an independent 
thinker, a careful and creative scientist, a critical reviewer, and a thoughtful story teller.  I 
appreciate the opportunities he gave me to explore in science, and I hope to keep his sense of 
optimism and enthusiasm with me always.    
To the current and past members of the Liu lab, I would like to thank all of you for 
your advice, training, and friendship.  I would particularly like to thank Flor Evangelista for 
her enduring friendship and scientific guidance.  It is difficult to imagine graduate school 
without Flor, and I will always be grateful for her support and proud to call her a colleague.  I 
thank Jaime Brozowski and Anne Weaver for their assistance managing our animal colonies.  
I would also like to thank Lan Lin, Ying Ching Liang, Peng Geng, Elizabeth Lessey, Julia 
Huang, Ming Lang Zhao, and Megan Meade for their help, ideas, and positive attitudes. 
I am also grateful to my other graduate school mentors, particularly the members of 
my thesis committee, Drs. Roland Tisch, Ed Collins, Jenny Ting, and Lishan Su.  Their 
thoughtful suggestions and wise advice were instrumental to my scientific progress.  I would 
like to acknowledge key members of the UNC Department of Dermatology, including Drs. 
Luis Diaz, David Rubenstein, and Ning Li.  Their clinical and scientific expertise was an 
amazing resource during my training.   
vii 
 
I was very fortunate to make three great friends on my first day of graduate school 
who have inspired me every step of the way.  To Monika Schneider, Mark Johnson, and 
Rachael Liesman, thank you for sharing this journey with me.  Thanks also to Aadra Bhatt 
and Sean McNally, two friends and colleagues I met a little later but who are just as dear. 
Finally, I would like to thank my family for their love and encouragement throughout 
graduate school and my life in general.  My parents Mike and Kim Leighty taught me from 
an early age to be intellectually curious and to pursue my dreams.  My sisters Michelle and 
Laura Leighty have supported and believed in me every step of the way.  Most importantly, I 
would like to thank my husband Matthew for his unwaveringly love and faith in me.   
  
viii 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES .................................................................................................................... x 
LIST OF FIGURES ................................................................................................................. xi 
LIST OF ABBREVIATIONS ................................................................................................. xii 
CHAPTER 1: BACKGROUND AND SIGNIFICANCE......................................................... 1 
                       1.1  BULLOUS PEMPHIGOID ........................................................................ 1 
                       1.1.1  Clinical Features of Bullous Pemphigoid in Humans .............................. 1 
                       1.1.2  Animal Models of Bullous Pemphigoid .................................................. 4 
                       1.1.3  Immunopathogenesis of Experimental BP in the Murine Model ............ 6 
                       1.1.4  Current Therapeutic Strategies For Treatment of Human BP ............... 13 
                       1.2.  MAST CELL BIOLOGY ........................................................................ 14 
                       1.2.1  MC Development and Function in the Skin .......................................... 15 
                       1.2.2  C5aR mediated MC Activation .............................................................. 17 
                       1.2.3  p38MAPK Signaling in MCs ................................................................. 18 
                       1.2.4  TNF-α mediated MC Activation ............................................................ 19 
                       1.2.5  MCs in Autoimmunity ........................................................................... 20 
                       1.3   SUMMARY AND CONCLUDING REMARKS ................................... 21 
ix 
 
                       1.4  REFERENCES ......................................................................................... 23 
CHAPTER 2: THE C5A RECEPTOR ON MAST CELLS IS CRITICAL FOR THE 
                        AUTOIMMUNE DISEASE BULLOUS PEMPHIGOID .............................. 41 
 
                       2.1 INTRODUCTION ..................................................................................... 42 
                       2.2  EXPERIMENTAL PROCEDURES ......................................................... 43 
                       2.3  RESULTS ................................................................................................. 49 
                       2.4 DISCUSSION ............................................................................................ 53 
                       2.5  REFERENCES ......................................................................................... 62 
CHAPTER 3: FUNCTIONAL INTERACTION BETWEEN COMPLEMENT 
                       AND THE PRO-INFLAMMATORY CYTOKINE TNF-α IN 
                       EXPERIMENTAL BULLOUS PEMPHIGOID  ............................................. 68 
 
                       3.1 INTRODUCTION ..................................................................................... 69 
                       3.2 EXPERIMENTAL PROCEDURES .......................................................... 71 
                       3.3  RESULTS ................................................................................................. 76 
                       3.4  DISCUSSION ........................................................................................... 81 
                       3.5  REFERENES ............................................................................................ 93 
CHAPTER 4: DISCUSSION ................................................................................................ 100 
                       4.1 INTRODUCTION ................................................................................... 100 
                       4.2 FINDINGS AND IMPLICATIONS ........................................................ 102 
                       4.3  REMAINING QUESTIONS AND FUTURE DIRECTIONS ............... 105 
                       4.4  CONCLUDING REMARKS .................................................................. 107 
                       4.5  REFERENCES ....................................................................................... 108 
x 
 
LIST OF TABLES 
 
 
Table 2.1.  Role of C5a receptor and p38 MAPK in experimental BP.   ............................... 61 
 
   
xi 
 
LIST OF FIGURES 
 
Figure 1.1   Organization of BP180 in human, mouse, and the NC16A+/+  
humanized mouse.…………………………………………………..…….…...5 
 
Figure 1.2   Mechanism of subepidermal blistering in experimental BP….…………….…7 
Figure 2.1   Level of C5a in the skin is significantly reduced in pathogenic 
IgG-injected mice lacking the classical pathway of complement………....…55 
 
Figure 2.2.  Mice lacking C5a receptor are resistant to experimental BP.........………..…56   
 
Figure 2.3.  Mice lacking C5aR show impaired p38MAPK activation  
induced by pathogenic antibodies……………………………………………57 
 
Figure 2.4  Blocking p38MAPK activation abolishes experimental BP………..………..58   
 
Figure 2.5  C5a activates p38MAPK of MCs in vivo and in vitro..……………...………59 
 
Figure 2.6.  MC reconstitution restores BP in MC-deficient mice. ………………………60 
 
Figure 3.1.   Pathogenic anti-mBP180 IgG induces BP blisters associated  
with an elevated level of TNF-α in mouse skin. ………………………….…84   
 
Figure 3.2.  TNF-α-deficient mice are resistant to experimental BP. ……………………85 
 
Figure 3.3.  Time-course of TNF-α expression during BP disease  
development in mice…………………………………………………………86 
 
Figure 3.4.  MC reconstitution restores BP in TNF-α-/- and MC-deficient mice……...…87 
 
Figure 3.5. C5aR on MCs are required for TNF-α release and skin blistering….…….…88 
 
Figure 3.6.  TNFR1 and not TNFR2 is required for experimental BP .………………..…89 
 
Figure 3.7.   Local reconstitution of MCs bearing TNFR1 and not TNFR2 
restores BP disease in TNFR-deficient mice.…………………….….………90   
 
Figure 3.8.   Experimental BP induced by patient anti-BP180 autoantibodies 
   depends on TNF-α………………….…………………………………..……91   
 
Figure 3.9.  `Proposed model for MC regulation of experimental BP……………......……..92
xii 
 
LIST OF ABBREVIATIONS 
 
Ab  Antibody 
BMZ  Basement membrane zone 
BP  Bullous pemphigoid 
BPAG  Bullous pemphigoid antigen 
BSA  Bovine serum albumin 
C3a  Complement component 3a 
C3aR  Complement component 3a receptor 
C5a  Complement component 5a 
C5aR   Complement component 5a receptor 
CD  Cluster of differentiation 
CHAPS 3-(3-cholamidopropyl)dimethylammonio-1-propanesulfonic acid 
CTMC  Connective tissue mast cell 
COLXVII Collagen seventeen 
DC  Dendritic cell 
DEJ  Dermal-epidermal junction 
ECL  Enhanced chemiluminescence  
ECM  Extracellular matrix 
F(ab)  Fragment (antigen binding) 
FADD  Fas associated death domain 
Fb  Factor B 
Fc  Fragment, crystallizable 
FcγIIIR Fragment, crystallizable gamma three receptor 
xiii 
 
g   Gravity 
GPCR  G protein coupled receptor 
GB  Gelatinase B 
GM-CSF Granulocyte macrophage colony stimulating factor 
GST  Glutathione S-Transferase 
HSC  Hematopoetic stem cell 
ICD  Intracellular domain 
IF  Immunofluorescence  
Ig    Immunoglobulin 
IL    Interleukin 
IVIG  Intravenous immunoglobulin   
H&E    Hematoxylin and eosin 
KC  Keratinocyte 
LC  Langerhans cell 
LPS  Lipopolysaccharide 
MAPK  Mitogen-activated protein kinase 
MAPKK Mitogen-activated protein kinase kinase 
MAPKKK Mitogen-activated protein kinase kinase kinase 
mBP180 Murine BP180 
MC   Mast cell 
mg  Milligram 
MIP-2  Macrophage inflammatory protein 2 
mL  Milliliter 
xiv 
 
μl  Microliter 
mM  Millimolar 
μM  Micromolar 
mMCP4 Mouse mast cell protease 4 
MΦ    Macrophage 
MPO  Myeloperoxidase 
MS  Multiple sclerosis 
MTMC Mucosal tissue mast cell 
NaCl   Sodium chloride 
NC    Non-collagen 
NE  Neutrophil elastase 
NFAT  Nuclear factor of activated T cells 
NF-kB  Nuclear factor-kappa B 
Ng  Nanogram 
OD   Optical density  
PMN    Polymorphonuclear neutrophil 
PVDF  Polyvinylidene fluoride 
rC5a  Recombinant complement component 5a 
RIP  Receptor-interacting protein 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM    Standard error of mean 
SODD  Silencer of death domain 
Th   T helper 
xv 
 
TLR  Toll-like receptor 
TNF    Tumor necrosis factor 
TNFR   Tumor necrosis factor receptor 
TRADD TNF-receptor associated death domain 
TRAF  TNF-receptor associated factor 
Treg   Regulatory T cell 
WT    Wild type 
 
 
 
 
 
CHAPTER 1 
BACKGROUND AND SIGNIFICANCE1 
 
 
1.1  BULLOUS PEMPHIGOID  
Bullous pemphigoid (BP) is a human autoimmune and inflammatory disease first 
described by the dermatologist Walter Lever in 1953 (1). BP is the most prevalent 
autoimmune skin blistering disease, with 10 new cases per million population reported 
annually in the United States (2).  Unlike many other autoimmune diseases, BP primarily 
afflicts men and the elderly, with an average age of onset in the 80s (3).  BP is associated 
with significant morbidity and mortality, with between 10% and 40% of patients dying 
within three years of disease onset (4, 5).  The global disease burden of BP is expected to 
increase over time as the population ages.  Although it is a relatively uncommon disease, BP 
is particularly useful as a paradigm for an organ-specific autoimmune disease  based on the 
well understood mechanism of pathogenesis.  
 
1.1.1  Clinical Features of Bullous Pemphigoid in Humans 
 BP is characterized by the presence of tense, fluid filled blisters on the skin (1).  
Blister formation occurs in areas where the basal keratinocytes of the epidermis detach from 
the underlying dermis (6).  This dermal-epidermal junction (DEJ) separation is associated 
                                                            
1 Portions of this chapter have been reproduced/amended from: Heimbach, L., Li, N., Diaz, 
L.A., and Liu, Z.  Experimental animal models of bullous pemphigoid.  G Ital Dermatol 
Venereol. 2009 144(4):423-31. 
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with a cellular inflammatory infiltrate in the upper dermis and the bullous cavity.  Eosinphils 
are the predominant cell type present, along with polymorphonuclear neutrophils (PMNs), 
lymphocytes, mast cells (MCs), and monocytes/macrophages (7-12).    Eosinophils, PMNs, 
and MCs are thought to be locally activated in the dermis by the multiple inflammatory 
mediators present in the lesional skin and blister fluid.   These mediators include granular 
proteins derived from degranulated leukocytes, such as eosinophil cationic protein, 
eosinophil major basic protein, and PMN-derived myeloperoxidase (MPO) (13-15), and 
chemoattractants and cytokines, such as C5a fragments, histamine, leukotriene B4, 
interleukin (IL)-1, -2, -4, -5, -6, -8, -15, tumor necrosis factor (TNF)-α, interferon-γ, 
RANTES, and eotaxin (16-22).    
 A hallmark of BP is the deposition of autoantibodies and complement components 
along the basement membrane zone (BMZ) of the skin (23, 24).  The humoral autoimmune 
reaction in BP is directed against components of the hemidesmosome, a cellular adhesion 
complex that anchors the basal keratinocytes of the epidermis to the underlying extracellular 
matrix (ECM) (24, 25).  A polyclonal repertoire of both circulating and tissue-bound 
autoantibodies targets two major hemidesmosomal antigens, the 230 kilodalton (kDa) protein 
termed BP230 or bullous pemphigoid antigen (BPAG) 1, and the 180 kDa protein termed 
BP180, BPAG2, or type XVII collagen (26-29).  BP230 localizes to the hemidesmosomal 
plaque within the intracellular domain of the keratinocyte (30, 31).  BP180 is a type II 
transmembrane protein, and the amino-terminal region also localizes to the intracellular 
hemidesmosomal plaque (30, 32, 33).  The carboxyl-terminal portion of BP180 extends into 
the extracellular milieu of the basement membrane zone (BMZ) and interacts with laminin-
332 and alpha-6 integrin to promote keratinocyte stability and adhesion (34, 35).  The 
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ectodomain of human BP180 consists of 15 collagen domains (designated C1 through C15) 
interspersed by 16 non-collagen sequences (NC1 through NC16A) (Figure 1.1) (32).   
NC16A is the largest of the non-collagen regions and is adjacent to the transmembrane 
domain of BP180.  Epitope mapping studies demonstrated that the NC16A domain of BP180 
harbors multiple epitopes recognized by autoreactive immunoglobulins (Ig) of IgE and IgG 
isotypes and IgG1 and IgG4 subclasses (36-40).  Serum titers of anti-NC16A autoantibodies 
are correlated with disease severity (37, 41, 42).  Together, these data demonstrate that 
BP180 is the key autoantigen in BP.   
 In addition to the humoral response directed against BP180, most BP patients also 
exhibit T cell mediated autoimmunity as well.  Autoreactive CD4+ T lymphocytes 
expressing memory cell surface markers recognize epitopes within the extracellular region of 
BP180, mostly clustering within the NC16A domain (43, 44).  The autoreactive T cells 
exhibit a Th1/Th2 mixed cytokine profile.  CD4+CD25+Foxp3+ regulatory T cells (Tregs), a 
subpopulation of T lymphocytes associated with downregulation of autoimmunity (45), do 
not appear to play a major role in BP pathogenesis.  Tregs are present in normal numbers in 
the circulation of BP patients, and numerous Tregs are found in the lesional and healthy skin 
of BP patients (46, 47).   Tregs isolated from BP patients are also functionally intact and are 
able to suppress T cell proliferation (47).  A recent study found that elevated levels of Th17 
cells, a subset of T lymphocytes associated with inflammation and tissue damage in 
autoimmunity (48), are found in the lesional skin of BP patients; however, no correlation 
between Th17 cell levels and disease severity were observed (46). Further research into Th17 
cell involvement in the pathogenesis of BP is needed.   
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1.1.2  Animal Models of Bullous Pemphigoid 
 Efforts to develop an animal model of BP date back to the early 1970s (49).  Based on 
the strong correlation between BP disease severity and serum anti-BP180 and anti-BP230 
antibody titers (24), researchers suspected that autoantibodies triggered blister formation.  In 
the first attempt to demonstrate human patient autoantibody pathogenicity in vivo, 
researchers transfused Rhesus monkeys with plasma from human BP patients (50).  Only 
limited autoantibody deposition was observed at the BMZ, and all three animals failed to 
develop blisters.  Attempts to elicit disease in mice by passively transferring purified BP 
patient autoantibodies were also unsuccessful (49).  Researchers were puzzled by the failure 
of the experiments, as two related autoimmune intraepidermal blistering diseases, pemphigus 
vulgaris and pemphigus foliaceus, were successfully modeled in mice using this same 
passive transfer strategy (51-53).   
A breakthrough came in 1993, when Zhi Liu and colleagues determined that the 
amino acid sequence of NC16A, the human BP180 protein recognized by pathogenic patient 
autoantibodies, is very poorly conserved in murine BP180 (mBP180) (54).    Human patient 
autoantibodies fail to cross react with the homologous murine antigen, termed NC14A 
(Figure 1.1), and thus do not trigger disease.  Liu et. al. then cloned the NC14A portion of 
mBP180 and expressed the peptide in DH5α cells as a glutathione S-transferase (GST) fusion 
protein.    New Zealand White rabbits were immunized with the purified mBP180 fusion 
protein and the polyclonal IgG fraction from the serum was collected. 
Neonatal Balb/c mice injected intradermally with purified rabbit anti-mBP180 IgG 
developed the key hallmarks of human disease, including clinical skin lesions, in vivo 
deposition of rabbit IgG and mouse C3 at the basement membrane by direct 
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immunofluorescence (IF), dermal-epidermal separation and an extensive inflammatory cell 
infiltration by H&E staining, with PMNs being the predominant cells (54).  
 
 
Figure 1.1 Organization of BP180 in human, mouse, and the NC16a+/+ humanized 
mouse.  The human form of BP180 (top) consists of 15 collagen domains (yellow) 
interspersed by 16 non-collagen domains.  The non-collagen domain closest to the cell 
membrane, NC16A (red), harbors the epitopes recognized by pathogenic autoantibodies.  In 
mouse (middle), BP180 consists of 13 collagen domains and 14 non-collagen domains.  
NC14A (black) is the murine homolog of NC16A, but the sequence is sufficiently divergent 
such that antibodies do not cross-react between the two regions.  In the humanized 
NC16A+/+ mouse, the NC16A region replaces the NC14A sequence in murine BP180. 
 
The murine model of experimental bullous pemphigoid developed in 1993 has proven 
to be an invaluable tool for understanding the etiopathogenesis of disease.  The research 
describing the cellular and inflammatory events that contribute to experimental BP 
development is reviewed in section 1.3 of this document.  However, the rabbit anti-mBP180 
IgG passive transfer model does not allow for experimentation with BP autoantibodies 
isolated from human clinical samples.  To assess the pathogenicity of human anti-BP180 
Collagen Domains
N C
NC16A
N C
NC14A
N C
NC16A
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autoantibodies, Liu et. al generated a novel mouse strain in which the murine BP180NC14A 
was replaced with the homologous human BP180NC16A epitope cluster region (Figure 1.1) 
(55).  The humanized NC16A (NC16+/+) mice injected with anti-BP180NC16A 
autoantibodies purified from human BP patients exhibit in vivo deposition of human IgG and 
mouse C3 at the basement membrane, dermal-epidermal separation, clinical blistering, and 
inflammatory cell infiltration.  A second humanized animal model was developed by Nishie 
et. al. that replaces the entire mBP180 protein with the human BP180 homolog (56).  Upon 
injection of human anti-BP180 autoantibodies, these mice (termed COLXVII-humanized) 
reproduce the DEJ separation at the lamina lucida, the deposition of human IgG along the 
DEJ, and the inflammatory cell infiltrate consisting of PMNs and eosinophils seen in human 
disease.  
 
1.1.3  Immunopathogenesis of Experimental BP in the Murine Model 
Development of in vivo systems to study an experimental BP model has allowed for 
great progress in defining the etiopathogenesis of disease.  The  rabbit anti-mBP180 IgG 
passive transfer model is easily adapted from use with Balb/c mice to numerous genetically 
modified mice to explore the requirement for a wide swath of inflammatory mediators in the 
development of experimental BP.  Specifically, the roles of pathogenic antibodies, the 
complement system, MCs, PMNs, and proteolytic enzymes have been elucidated in the 
context of the rabbit anti-mBP180 IgG passive transfer model.  Figure 1.2 summarizes the 
key steps identified in the mechanism of subepidermal blistering in experimental BP. 
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mapped using a panel of deletion mutants of the mBP180 ectodomain in concert with 
immunoadsorption and immunoblotting assays (58).  These mapping studies demonstrated 
that pathogenic anti-BP180 antibodies recognize a 9-12 amino acid stretch within the murine 
BP180 NC14A region of the antigen (58).  This epitope overlaps the region of the human 
BP180 NC16A containing the immunodominant epitopes recognized by human BP 
autoantibodies, supporting the relevance of the murine system as a model for human disease.  
Epitope mapping studies in the humanized mouse are not yet published.  
‐Complement- 
 
Complement activation occurs via three pathways- the classical, lectin, and 
alternative pathways (59).  The classical pathway initiates when antigen-antibody binding 
induces a conformational change in the Fc portion of the antibody, enabling the antibody to 
bind C1.  The C1r subunit is converted to a serine protease that cleaves C4 and C2 to C4a + 
C4b and C2a + C2b.  C4b associates with C2a to form the C3 convertase, while C4a and C2b 
diffuse and promote inflammation.  The alternative pathway does not involve antibody, but 
instead initiates when the labile thioester bond in the C3 molecule spontaneously hydrolyses 
to produce C3a and C3b.  C3b associates with factor B, which is cleaved by factor D to form 
C3bBb, the C3 convertase.  The mannose binding lectin pathway is activated when mannose 
binding lectin binds sugars on the surface of a bacteria.  This binding attracts MASP-1 and 
MASP-2 to interact with the lectin, and leads to the cleavage of C2 and C4 and generation of 
the C3 convertase akin to that of the classical pathway.  All three pathways of complement 
activation converge in function at the formation of the C3 convertase capable of cleaving C3 
to C3a and C3b.  C3b associates with the C3 convertase to form the active C5 convertase; 
this C5 convertase cleaves C5 into C5a and C5b.   The anaphylotoxin C5a is a potent 
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chemoattractant and inflammatory mediator, and acts on a wide range of myeloid and 
lymphoid lineage cells, including skin MCs (60, 61).  C5b binds to the surface of a target cell 
and initiates the assembly of the membrane attack complex.  Subsequent binding of 
additional serum proteins (C6, C7, C8, C9, sequentially and with many C9s binding) 
generates an amphiphilic helix that inserts into the lipid bilayer and creates a membrane 
spanning channel.  Disruption of the cell membrane integrity leads to lysis of the cell.  C3b is 
also involved in the innate immune response by directly coating particulate antigen and 
immune complexes, leading to their enhanced opsonization by macrophages. 
Autoantibodies bind to basement membrane antigens and activate complement in 
human BP.  Lesional skin from BP patients exhibits deposition of complement components 
along the DEJ, and the murine models of experimental BP recapitulates this feature of human 
disease (23, 54-56). In the rabbit anti-mBP180 IgG passive transfer model, complement 
activation is required for disease development. Both BALB/c mice depleted of complement 
by pretreatment with cobra venom and C5-deficient mice are resistant to experimental BP.  
In turn, reconstitution of the C5-deficient mice with recombinant C5a restores disease 
susceptibility (62).   
F(ab’)2 fragments generated from the pathogenic anti-mBP180 IgG cannot induce 
subepidermal blisters in C5-sufficient mice (62), indicating a key role for the classical 
pathway of complement activation.  Similarly, mice deficient in complement component C4 
(specific for the classical and lectin pathways), but not in factor B (specific for the alternative 
pathway), are resistant to BP (63). Wild-type mice depleted of complement component C1q 
(also specific for the classical pathway) fail to activate MCs or develop BP skin lesions when 
injected with pathogenic IgG (63).  These data indicate that the classical pathway of the 
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complement activation plays a major role in development of BP disease through the 
generation of C5a (64).   
-Mast Cells- 
 
MCs are key effector cells involved in innate and adaptive immunity, as well as 
allergic and anaphylactic reactions (65, 66).  MCs are found in particularly high 
concentrations in the connective tissues just below the epithelial surfaces of the body, such as 
the submucosal tissues of the gastrointestinal and respiratory tracts and the dermis of the 
skin, positioning them as key sentinels against external challenges.  Upon activation, MCs 
degranulate and release preformed bioactive compounds from their secretory granules, 
including histamine, cytokines, proteoglycans, and proteases (67).  Together, these 
inflammatory mediators increase the permeability of local blood vessels and recruit effector 
cells to the site.  In addition to their role in protection against environmental stimuli, MCs are 
also implicated in chronic inflammatory and autoimmune diseases.  Mice lacking MCs are 
partially or completely protected from disease in animal models of multiple sclerosis, 
collagen-induced arthritis, and BP (64, 68, 69).   
Intact and degranulated MCs are commonly observed in the dermis of BP patients, 
and histamine and other MC-derived factors are present in high concentrations in the affected 
skin (12, 13, 18, 70).  Mice injected with pathogenic anti-mBP180 antibodies exhibit 
extensive MC degranulation in the lesional skin, similar to that observed in human BP (12, 
64).  MC-deficient mice are resistant to experimental BP, but reconstitution of these mice 
with MCs restores susceptibility to disease.  MC activation precedes PMN infiltration, and 
either the absence of MCs or the inhibition of MC degranulation prevents PMN infiltration 
and blister formation.  However, MC-deficient mice reconstituted locally with PMNs, or 
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injected locally with PMN chemoattractants IL-8 or C5a form blisters in response to anti-
mBP180 IgG.  These results suggest that MCs release proinflammatory cytokines critical for 
PMN recruitment (64).  
 Skin-resident MCs function in both an IgE dependent and IgE independent manner.  
The IgE independent activation of MCs can be mediated by products of complement 
activation, proinflammatory cytokines, Toll-like receptors (TLRs), or by Fc receptors (71).  
Skin MCs express C5a receptor (C5aR, or CD88) (72), and interaction of C5a and C5aR 
induces MC degranulation and the release of proinflammatory cytokines.  
‐Neutrophils- 
 
 PMNs, produced in vast numbers in the bone marrow, circulate in the blood and act 
as the front line of defense against microorganisms that breach skin and mucous membrane 
barriers.  PMNs extravasate into tissue under the direction of local endothelial cells, which 
are activated by inflammatory signals such as TNF-α, IL-1β, or IL-17. (73).  The activated 
local endothelial cells express the adhesion molecules P-selectin, E-selectin, intracellular 
adhesion molecule (ICAM)-1, ICAM-2, and vascular adhesion molecule (VCAM)-1, which 
engage their ligands on the PMNs to capture rolling PMNs from the circulation. The 
endothelial cells also produce the PMN chemoattractant and activators IL-8 and macrophage 
inflammatory protein 2 (MIP-2) (73).  PMNs have a wide range of effector capabilities, 
including phagocytosis of microbes, production of reactive oxygen species, release of lytic 
enzymes, synthesis of both proinflammatory and anti-inflammatory mediators, and capture of 
microbes via fibrillary networks termed neutrophil extracellular traps (NETs) (74-76).  PMNs 
are involved in the pathology of numerous chronic inflammatory and autoimmune disorders, 
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including chronic obstructive pulmonary disease, systemic lupus erythematosus, small vessel 
vasculitis, inflammatory arthritis, and BP (77-82). 
PMN infiltration is required for the development of experimental BP, and there is a 
strong correlation between severity of disease and number of infiltrating PMNs (80).  
Depletion of PMNs with anti-PMN antibodies, or disruption of the events upstream of PMN 
infiltration (namely complement activation and MC degranulation), renders mice resistant to 
BP blister formation.  However, complement system impairments and MC deficiencies do 
not block the pathological effects of BP180 autoantibodies unless PMN infiltration is 
prevented as a consequence of the deficiency.  Mice deficient in complement or MCs are still 
susceptible to experimental BP when PMNs are recruited by injection with IL-8 or rC5a (63, 
64).  Thus, complement activation and MC degranulation mediate disease progression by 
promoting PMN recruitment to the skin.  These data demonstrate that infiltrating PMNs are 
the critical cells that directly mediate tissue injury at the DEJ, leading to BP skin blisters. 
‐Proteolytic Enzymes- 
 
 PMNs promote skin injury by release of proteolytic enzymes.  The FcγIIIR on the cell 
surface of infiltrating PMNs interacts with the Fc portion of the tissue-bound pathogenic anti-
mBP180 IgG  (83).  PMNs activated by the Fc-FcγIIIR molecular interaction secrete 
proteolytic enzymes known to degrade the ECM, including neutrophil elastase (NE) and 
gelatinase B (GB, also called matrix metalloproteinase-9) (83).  A lack of either of these two 
enzymes blocks blister formation in mice (84, 85).   In vitro, although both GB and NE are 
capable of degrading the recombinant BP180 protein, only NE produces DEJ separation 
when incubated with skin sections (84, 86).  In vivo, the degradation of BP180 depends on 
NE activity (87). These findings suggest that GB is the upstream actor that proteolytically 
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inactivates the physiological inhibitor of NE (α1-proteinase inhibitor), which allows for 
unmitigated NE cleavage of ECM proteins (including BP180), resulting in DEJ separation 
(88).  MCs also release proteolytic enzymes upon degranulation (67).  Mouse mast cell 
protease-4, the likely murine homolog of human MC chymase, directly degrades BP180, and 
also activates GB (89).   
-Other Inflammatory Cells- 
 
Anti-mBP180 autoantibodies trigger experimental BP with equivalent severity in WT 
mice and mice deficient in T and B lymphocytes (90), suggesting that B and T cells do not 
play a role in this animal model.  The limitations of the passive transfer injection model 
prevent investigation of the events that precipitate loss of tolerance and the generation of 
autoreactive B cells.  Indeed, little is understood about the etiology of BP or lymphocyte 
regulation.  Macrophages (MΦ) play an accessory role to MCs in PMN recruitment upon 
pathogenic antibody injection (90).  MΦs are activated downstream of MCs, and they serve 
to amplify the PMN recruitment mediated by MCs.   
 
1.1.4  Current Therapeutic Strategies For Treatment of Human BP 
 The mortality rate for BP is high, reported to be between 12% and 40% in the first 
three years after diagnosis (4, 5).  The conventional therapy for BP over the past several 
decades has been high-dose, long-term systemic oral corticosteroids and immunosuppressive 
agents (91).  However, long term use of corticosteroids is associated with deleterious health 
effects, including severe infection, diabetes mellitus, osteoporosis, hypertension, renal 
failure, lymphoma, and squamous cell carcinoma (92).  The negative side effects of 
immunosuppression therapy may account for a significant portion of the morbidity and 
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mortality associated with BP.  Even when disease is successfully treated, up to 45% of 
patients suffer a relapse within six months of cessation of therapy (93), exacerbating the need 
for novel therapeutic interventions.   
 In the past ten years, clinical management of BP has shifted away from oral 
corticosteroids in favor of topical corticosteroids (94).  However, topical treatments are not 
always feasible for cases of extensive blistering, particularly in elderly patients who maybe 
be bedridden or without the mobility to apply medications regularly.   
 Patients who fail both oral and topical corticosteroid treatment may be treated with 
biologicals such as intravenous immunoglobulin (IVIG) or rituximab (95).    Patients treated 
with IVIG receive huge amounts of pooled IgG isolated from thousands of healthy human 
donors (96).  The exact mechanism of IVIG is debated, however, there is compelling 
evidence that IVIG decreases the prevalent of pathogenic antibodies in circulation by 
increasing the rate of catabolism of IgG (97).  Rituximab targets the CD20 molecule on the 
surface of B cells, depleting the antibody producing cells from circulation (98).  No 
randomized controlled trials have been performed for either of these therapies yet, but 
anecdotal evidence suggests that these biologic approaches to treatment of BP offer treatment 
alternatives for patients (99, 100).       
 
1.2  MAST CELL BIOLOGY 
 MCs are innate immune cells primarily distributed in tissues that contact the external 
environment, such as the skin, airways, and the intestinal mucosa (101).  While widely 
known as the culprits in type I hypersensitivity responses, MCs are now known to participate 
in host defense, modulation of innate and adaptive immune responses, angiogenesis, wound 
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healing, and tissue homeostasis and remodeling (102).  Better understanding the mechanisms 
of MC activation, signaling, and cross-talk with other members of the immune system  
presents new opportunities for treatment of human disease.   
 
1.2.1  MC Development and Function in the Skin 
 MCs develop from hematopoietic stem cells (HSC), the common precursor to 
lymphocytes, granulocytes, and monocytes.  The HSC precursors develop into 
CD34+/CD117 (or cKit)+/CD13+ multipotent hematopoietic progenitors (103, 104).  
Committed MC progenitors exit the bone marrow, circulate in the peripheral blood, and 
undergo final maturation under the direction of microenvironmental cues from the tissue 
where the MCs stake long-term residence (105-109).  Final MC maturation in the peripheral 
tissues is regulated by the MC growth factors stem cell factor (SCF, or c-kit ligand) and IL-3 
(110, 111), as well as tissue specific factors.  MC populations exhibit considerable 
heterogeneity between tissue sites, based on tissue-specific final maturation.   
The identities of the factors that promote homeostatic MC progenitor recruitment to 
the skin and regulate development are not known (112).  In mice, nearly all skin MCs are 
connective tissue MCs (CTMCs) and have granules rich with histamine, tryptase, chymase, 
carboxypeptidase and cathepsin G-like proteinase, while MCs in the bowel mucosa and 
airways are predominantly mucosal tissue MC (MTMCs) and have granules that contain 
either tryptase and histamine or chymase, carboxypeptidase, and histamine but not tryptase 
(113-115).  This same pattern of tissue-based protease distinction is observed in human MCs.  
Skin and peritoneal cavity MCs are categorized as MCCT, indicating that the granules contain 
both tryptase and chymase (116).   
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MCs contribute to host defense by acting as sentinels against pathogens that breach 
the epidermal barrier.  MCs are distributed throughout the dermis, but are greatly enriched in 
the area immediately below the DEJ, a site dense with small blood vessels (117).  This 
proximity to the microvasculature enables MCs to act rapidly both locally and systemically.  
Localization to the DEJ also enables MCs to readily communicate with the two main 
sentinels of the epidermis, the keratinocytes (KCs) and Langerhans cells (LC), a class of 
specialized dendritic cell (DC) (118).  KCs and LCs produce a battery of antimicrobial 
peptides, chemotactic proteins, and cytokines, including IL-1 (α and β) and TNF-α (119-
121).  IL-1 stimulated MCs secrete IL-3, IL-6, IL-9, and TNF-α, and TNF-α stimulated MCs 
secrete IL-1 and upregulate FcγR expression (122).  Together, these proinflammatory factors 
can act on endothelial cells to promote local inflammation and recruit leukocytes to the skin, 
including perhaps additional MC progenitors (112, 123).   
TLRs enable MCs to directly respond to microbial agents than penetrate beyond the 4 
to 5 cell layers of the epidermis and into the dermis (71).  Extensive experimental evidence 
demonstrates that MCs respond to bacterial membrane components such as 
lipopolysaccharide (LPS) and peptidoglycan (PGN) via TLR-4 and TLR-2.  Mouse MCs 
stimulated with LPS or PGN secrete TNF-α and IL-6 without degranulation in a TLR-
dependent manner, and mice lacking TLR-4 fail to recruit sufficient PMNs to clear bacterial 
infections (124-129).  In vitro evidence suggests roles for TLR-9, TLR-3, TLR-1, and TLR-6 
in MC recognition of pathogen associated molecular patterns (130-134). 
MCs are able to indirectly respond to pathogens via their complement receptors 
(discussed in Section 1.2.2) and their Fc receptors.    FcγRs on MCs bind the Fc portion of 
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pathogen-specific antibodies, and cross-linking of the FcγRs by the polyvalent antigen on the 
pathogen results in MC degranulation and release of proinflammatory mediators (135, 136).  
FcR signaling can also activate MCs in response to bacterial superantigens, such as 
Streptococcus aureus protein A (137).    
 
1.2.2  C5aR mediated MC Activation 
 The anaphylatoxin C5a interacts with two C5a receptors, C5aR (also called CD88) 
and the C5a receptor-like 2 (C5L2) (61).  Both C5aR and C5L2 are broadly expressed by 
cells of both myeloid and non-myeloid lineages, including MCs (61, 138-142).  C5aR is the 
classically described ligand for C5a, while C5L2 was considered until very recently to be 
non-signaling decoy receptor that served to dampen C5a-mediated inflammation (141).  
Recent studies have uncovered a functional signaling role for C5L2 (143, 144), however, the 
vast majority of the understood C5a-mediated signaling is facilitated by C5aR. 
 C5a is a G protein coupled receptors (GPCRs) (145, 146).  Members of the GPCR 
family are characterized by their seven transmembrane-spanning domains, and they function 
by coupling to intracellular heterotrimeric G proteins (147).   The G protein is comprised of 
an α, β, and γ subunit.  When inactive, the G-α subunit is bound to GDP, and is associated 
with the β and γ subunits.  GPCR ligation causes a conformational change to the intracellular 
portion of the receptor, enabling it to act as a guanine nucleotide exchange factor.  The G-α 
releases GDP and binds GTP, which causes the β and γ subunits to dissociate from G-α.   G-α 
and G-βγ activate second messengers, including cyclic AMP, phospholipase C, and 
phosphoinositide 3-kinase.  Ultimately, the intracellular signaling cascade leads to production 
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of the transcription factors nuclear factor κB (NFκB), nuclear factor of activated T cells 
(NFAT), and activation protein-1 (AP-1), which modulate gene expression (148).   
 In the case of pathogen assault, complement activation may occur by the classical or 
mannose binding lectin pathways.  While many inflammatory cells (notably PMNs) express 
complement receptors, MCs are optimally positioned at the DEJ to respond to C5a. MCs 
express other complement-component receptors, including C3aR (the ligand for C3a) and 
CR3 (the ligand for C3b), however, degranulation occurs primarily as a result of activation of 
C5aR (71). Degranulation results in release of TNF-α, histamine, proteases, GM-CSF, IL-6, 
IL-1, and leukotriene C (71). 
   
1.2.3  p38MAPK Signaling in MCs 
 p38MAPK is a key signaling molecule involved in translating extracellular 
environmental conditions, particularly inflammatory conditions, into cellular responses 
(149).  There are four isoforms of p38MAPK, designated –α, -β, -γ, and –δ; MCs express the 
–α form exclusively (150).  p38MAPK is a serine/threonine kinase, thus, it exerts biological 
effect by phosphorylating proteins. 
 p38MAPK can be activated by numerous extracellular stimuli, including endotoxins, 
reactive oxygen species, ultraviolet radiation, TNF-α, IL-1, and TGF-β (151).  Upstream of 
p38MAPK, interaction, mitogen-activated protein kinase kinase kinases (MAPKKKs) are 
activated in a GTPase-dependent manner.  The MAPKKKs phosphorylate the  MAPK 
kinases MKK3, MKK4, and MKK6, which in turn activate p38 via phosphorylation of the 
Thr180 and Try 182 residues.  Activated p38MAPK facilitates the stabilization and increased 
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transcription of mRNAs for proinflammatory cytokines and receptors associated with 
inflammation (151).   
 The p38MAPK pathway plays a key role in numerous immune and inflammatory 
diseases, including rheumatoid arthritis and the skin autoimmune disease pemphigus vulgaris 
(152-154).  In PMNs and monocytes, the interaction of C5a and C5aR leads to activation of 
p38MAPK (155-157).  MC activation via antigen crosslinking of surface IgE molecules leads 
to p38MAPK activation and cytokine release (158), however, p38MAPK activation upon 
engagement of the C5aR on MCs has not yet been reported.  
 
1.2.4  TNF-α mediated MC Activation 
 TNF-α has been exhaustively described as a product released by MCs (159).  Less is 
known, however, about the effect of TNF-α on MCs themselves.  MCs stimulated by KC and 
LC-derived TNF-α secrete IL-1 and upregulate FcγR expression (122, 160).  In cultured 
human lung MCs stimulated with SCF and anti-IgE, TNF-α was shown to feed back on the 
MCs to promote enhanced NF-kB activation (161).  NF-kB promotes transcription of a wide 
array of pro-inflammatory cytokines, suggesting that a positive autocrine feedback loop may 
enable MCs to drive inflammation.      
TNF-α signals through the TNF-α receptors (TNFRs) TNFR1 and TNFR2, though 
TNFR1 mediates the majority of the biological activities of TNF-α (162).  Ligation of 
TNFR1 releases the inhibitory protein silencer of death domains (SODD) from TNFR1’s 
intracellular domain (ICD), which enables ICD to be recognized by the adaptor protein TNF 
receptor-associated death domain (TRADD) (163).  TRADD serves as a dock for additional 
adaptor proteins that recruit signaling enzymes to the signaling complex.  These adaptors 
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include TNFR-associated factor 2 (TRAF2), which can activate MAPKKKs, including 
MEKK1 and ASK1.  The adaptor Fas-associated death domain (FADD) recruits caspase-8 to 
the signaling complex, where it promotes progression of apoptosis.  Receptor-interacting 
protein (RIP) is yet another adaptor recruited by TRADD, and RIP mediates NF-kB 
activation.   
   
1.2.5  MCs in Autoimmunity 
 MCs are potent effector cells in the innate immune response to infection in large part 
due to the many avenues that lead to MC activation.  However, inappropriate MC activation 
outside of the context of pathogen invasion can result in significant pathology and 
autoimmunity (164).  The role of MCs in BP is described in Section 1.1.3.    In multiple 
sclerosis, MCs accumulate in the central nervous system plaque lesions and at sites of 
inflammatory demyelination (165-167).  MC-deficient mice are protected from experimental 
autoimmune encephalomyelitis, an animal model of MS, further supporting the case of MC 
involvement in disease (69). Similarly, MC-deficient mice are not susceptible to 
autoantibody-induced arthritis (68).  In human rheumatoid arthritis patients, elevated 
numbers of MCs are present in the synovial compartments, along with high levels of MC-
products including TNF-α, IL-1, IL-17, and tryptase.(168, 169).  There is also evidence that 
MCs contribute to pathology in Type 1 diabetes.  Cromolyn, a compound that prevents MC 
degranulation, significantly delays onset of disease in the spontaneously diabetic 
BioBreeding mouse (170).  Furthermore, activated MCs are found in the pancreatic lymph 
nodes of diseased mice (170).  
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 In the case of experimental BP, the data are clear: MCs attract PMNs to the skin, and 
PMNs do the damage (see section 1.1.3).  However, MCs interact with many types of 
immune cells, making the mechanisms by which MCs regulate autoimmunity far more 
complex than the experimental BP model predicts.  MC-derived products are known to 
influence the migration, maturation, and function of DCs, effector T cells and B cells (171, 
172).  Intriguingly for the consideration of autoimmunity, MCs also interact with Tregs and 
Th17 cells (164).   One well-defined avenue of Treg-MC interaction occurs via OX40, a 
molecular constitutively expressed on MCs, and OX40L, a protein constitutively expressed 
by Tregs.  When OX40-OX40L interact, MCs can impair Treg suppression of effector T 
cells, and Tregs are able to downregulate FcεR1 expression on MCs and prevent FcεR1-
mediated degranulation(173-175) .  MCs can produce Th17/Treg polarizing cytokines, 
including IL-6, IL-21, IL-23, and TGFβ.  In vitro, MCs can drive Treg or Th17 cell 
differentiation (175). Conceivably, MCs could perform this same polarizing role at sites of 
secondary activation and T cell priming.  
  
1.3   SUMMARY AND CONCLUDING REMARKS 
 The murine IgG passive transfer model of BP developed by Liu et al in 1993 has 
facilitated dissection of the mechanism of disease progression in experimental BP.  After 
nearly 20 years of experimentation, it is clear that BP pathogenesis proceeds through 
activation of MCs, but the mechanism of MC activation and the consequences of this 
activation are not clear.  MCs express a number of types of receptors capable of responding 
to proinflammatory ligands, including C5aR.  Taken with the evidence that complement 
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activation occurs upstream of MC degranulation, the C5aR is a promising candidate for 
facilitating MC signaling. 
 The primary objective of this dissertation was to elucidate the cellular events that 
occur immediately upstream and downstream of MC degranulation in experimental BP.  Our 
central hypothesis is that complement components activate MCs, and proinflammatory 
compounds released from the MCs drive pathology and blistering.  In chapters 2 and 3, we 
described studies that test this hypothesis using a series of knockout mice and MC 
reconstitution experiments.  We found that MCs are activated by the binding of C5a to C5aR.  
C5a-C5aR interaction leads to activation of p38MAPK and MC degranulation.  MC 
degranulation releases TNF-α, and TNF-α acts in an autocrine manner on MC TNFR1 to 
promote disease development.  Our findings highlight the potential for cross-talk between the 
complement and TNF-α mediated pathways of MC activation, and also support three 
potential therapeutic targets for treatment of BP. 
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CHAPTER 2 
THE C5A RECEPTOR ON MAST CELLS IS CRITICAL FOR THE AUTOIMMUNE 
SKIN BLISTERING DISEASE BULLOUS PEMPHIGOID2 
 
Bullous pemphigoid (BP) is an autoimmune skin blistering disease characterized by the 
presence of autoantibodies against the hemidesmosomal proteins BP230 and BP180. In the 
IgG passive transfer mouse model of BP, subepidermal blistering is triggered by anti-BP180 
antibodies and depends on the complement system, mast cell (MC) degranulation, and 
neutrophil infiltration. In this study, we identify the signaling events that connect the 
activation of the complement system and MC degranulation. We found that mice deficient in 
MCs or C5a receptor (C5aR) injected with pathogenic anti-BP180 IgG failed to develop 
subepidermal blisters and exhibited a drastic reduction in p38MAPK phosphorylation 
compared to wild-type (WT) mice. Local reconstitution with MCs from WT but not C5aR-
deficient mice restored high levels of p38MAPK phosphorylation and subepidermal 
blistering in MC-deficient mice. Local injection of recombinant C5a (rC5a) induced 
phosphorylation of p38MAPK in WT, but not MC-deficient mice. Cultured mouse MCs 
treated with rC5a exhibited a significant increase of p38MAPK phosphorylation and MC 
degranulation. Taken together, these data demonstrate that C5a interacts with C5aR on MCs, 
                                                            
2 Reproduced/amended from: Heimbach, L., Li, Z., Berkowitz, P., Zhao, M., Li, N., 
Rubenstein, D.S., Diaz, L.A., Liu, Z. The C5a receptor on mast cells is critical for the 
autoimmune skin-blistering disease bullous pemphigoid.  J Biol Chem 286(17): 15003-9. 
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and that this C5a-C5aR interaction triggers activation of the p38MAPK pathway, subsequent 
MC degranulation, and ultimately BP blistering. 
 
2.1 INTRODUCTION 
Bullous pemphigoid (BP) is an acquired skin autoimmune blistering disease 
characterized by the presence of circulating and tissue bound autoantibodies against two 
major hemidesmosomal proteins, BP230 (BPAG1) and BP180 (BPAG2 or type XVII 
collagen) (1-11). These anti-hemidesmosomal autoantibodies, along with complement 
components, are deposited along the basement membrane at the dermal-epidermal junction 
(DEJ) of perilesional skin (12-14).  Basal keratinocytes detach from the underlying dermis, 
leading to blister formation (5).  Using an animal model of BP in which neonatal BALB/c 
mice are injected with anti-murine BP180 (mBP180) antibodies, we previously demonstrated 
that dermal-epidermal separation is triggered by anti-BP180 IgG and depends on 
complement activation, mast cells (MCs), and neutrophils (PMNs) (15-17).  The binding of 
pathogenic IgG to BP180 activates the classical pathway of the complement and leads to MC 
degranulation, PMN recruitment, and subsequent skin blistering (18). However, the cellular 
processes linking complement activation and MC degranulation are not defined in BP.   
Complement activation via the classical, alternative, and lectin pathways generates the 
anaphylotoxin C5a (19).  A potent chemoattractant and inflammatory mediator, C5a acts on a 
wide range of myeloid and lymphoid lineage cells, including skin MCs (20, 21).  Skin MCs 
express C5a receptor (C5aR, or CD88) (22), and interaction of C5a and C5aR induces MC 
degranulation and the release of proinflammatory cytokines such as interleukin 1 (IL-1), IL-
6, tumor necrosis factor alpha (TNF-α), and granulocyte macrophage colony stimulating 
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factor (GM-CSF) (23).  In PMNs and monocytes, the interaction of C5a and C5aR leads to 
activation of p38 mitogen activated protein kinase (p38MAPK) (24-26).  p38MAPK is a key 
signaling molecule involved in translating extracellular environmental conditions, 
particularly inflammatory conditions, into cellular responses (27, 28).  MC activation via 
antigen crosslinking of surface immunoglobulin E (IgE) molecules leads to p38MAPK 
activation and cytokine release (29), however, p38MAPK activation upon engagement of the 
C5aR on MCs has not yet been reported.  
In this work, we examined the role of C5a-C5aR interaction in the progression of 
experimental BP.  We found that C5a interacts with C5aR on MCs, and that this C5a-C5aR 
interaction triggers activation of the p38MAPK pathway and ultimately induces MC 
degranulation and subsequent BP blistering.  
 
2.2  EXPERIMENTAL PROCEDURES 
Materials.  The p38MAPK inhibitor SB203580 and the inactive analog SB202474 
were purchased from Calbiochem (La Jolla, CA).  Rabbit anti-phospho-p38MAPK antibody 
was purchased from Cell Signaling (Danvers, MA), and rabbit anti-p38MAPK antibody was 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  The recombinant C5a was 
purchased from R&D System (Minneapolis, MN). Protein concentration was determined 
with the RC DC protein assay purchased from Bio-Rad Laboratories (Hercules, CA).  The 
ECL Western blotting analysis kit was purchased from GE Healthcare (Piscataway, NJ).  
Laboratory animals.  Breeding pairs of C57BL/6J, C4-deficient (C4-/-), MC-
deficient WBB6F1-Kitw/Kitw-v (MC-/-), and C5a receptor-deficient (C5aR-/-) mice were 
purchased from Jackson Laboratories (Bar Harbor, ME) and maintained at the University of 
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North Carolina at Chapel Hill.  The MC deficiency in Kitw/Kitw-v mice is caused by distinct 
mutations in MC c-Kit (30). Neonatal mice (24-36 hours old with body weights between 1.4 
and 1.6 grams) were used for passive transfer experiments.  All animal care and animal 
experiments were approved by the UNC Animal Care Committee and were in accordance 
with the National Institutes of Health guidelines. 
Preparation of pathogenic anti-BP180 IgG.  The preparation of recombinant 
murine BP180 (mBP180) and the immunization of New Zealand white rabbits were 
performed as previously described (31-33).  Briefly, a segment of the ectodomain of the 
murine BP180 antigen (31) was expressed as a glutathione S-transferase (GST) fusion 
protein using the pGEX prokaryotic expression system (Pharmacia LKB Biotechnology, 
Piscataway, NJ). The murine BP180 fusion protein, designated GST-mBP180ABC 
containing NC14A and half of C13 domains (Figure 1.1), was purified to homogeneity by 
affinity chromatography using a glutathione-Agarose column (33).  New Zealand White 
rabbits were immunized with the purified mBP180 fusion protein and the IgG fraction from 
the serum (designated R621) was purified as previously described (31).  The IgG fractions 
were concentrated, sterilized by ultrafiltration and the protein concentrations determined by 
OD280 [E (1%, 1 cm) = 13.6]. The titers of anti-murine BP180 antibodies in both the 
unfractionated rabbit serum and in the purified IgG fraction were assayed by indirect 
immunofluorescence (IF) using mouse skin cryosections as substrate.  The antibody 
preparations were also tested by immunoblotting against the GST-mBP180ABC fusion 
protein.  The pathogenicity of these IgG preparations was tested by passive transfer 
experiment as described below.   
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Induction of experimental BP and clinical evaluation of animals.   Neonates were 
given on the back one i.d. injection of a sterile solution of IgG in PBS (50 μl IgG, 2.5 mg 
IgG/g body weight) as described elsewhere (31). The skin at the IgG-injection site of the 
mice from the test and control groups was examined at different time points after the IgG 
injection.  The extent of cutaneous disease was scored as follows: "(-)", no detectable skin 
disease; "1+", mild erythematous reaction with no evidence of the epidermal detachment sign 
[this sign was elicited by gentle friction of the mouse skin which, when positive, produced 
fine, persistent wrinkling of the epidermis]; "2+", intense erythema and epidermal 
detachment sign involving 10-50% of the epidermis in localized areas; and "3+", intense 
erythema with frank epidermal detachment sign involving more than 50% of the epidermis in 
the injection site. 
After clinical examination, the animals were sacrificed, and skin and serum 
specimens were obtained. Skin sections were used for a) routine histological examination by 
light microscopy (H/E staining) to localize the lesional site and PMN infiltration, b) toluidine 
blue staining to quantify MCs and MC degranulation, c) direct IF assays to detect rabbit IgG 
and mouse C3 deposition at the BMZ, and d) myeloperoxidase (MPO) enzymatic assay to 
quantify the PMN accumulation at the skin injection site described below.  The sera of 
injected animals were tested by indirect IF techniques to determine the titers of rabbit anti-
mBP180 antibodies using mouse skin cryosections as the substrate.  Direct and indirect IF 
studies were performed as previously described (31) using commercially available FITC-
conjugated goat anti-rabbit IgG (Kirkeggard & Perry Laboratories Inc.).  Monospecific goat 
anti-mouse C3 IgG was purchased from Cappel Laboratories. 
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Quantification of PMN accumulation at the skin site.  MPO activity in skin sites of 
the injected animals was assayed as a measure of PMN infiltration as described (34, 35).  A 
standard reference curve was established using purified MPO (Athens Research and 
Technology, Inc., Athens, Georgia).  The skin samples were extracted by homogenization in 
an extraction buffer containing 0.1 M Tris-Cl, pH 7.6, 0.15 M NaCl, 0.5% hexadecyl 
trimethylammonium bromide.  MPO activity in the supernatant fraction was measured by the 
change in optical density at 460 nm resulting from decomposition of H2O2 in the presence of 
o-dianisidine.  MPO content was expressed as units of MPO activity/mg protein.  Protein 
concentrations were determined by the Bio-RAD dye-binding assay using bovine serum 
albumin (BSA) as a standard. 
Determination of C5a levels in skin.  Skin from the IgG injection site of the 
diseased and control mice was mechanically homogenized in PBS to extract proteins.  The 
level of mouse C5a in the skin was measured by ELISA (R&D Systems, Minneapolis, MN).  
Microtiter plates were coated with a rat anti-mouse C5a antibody, incubated with skin protein 
extracts, followed by goat anti-mouse C5a detection antibody, and then developed and read 
at OD492nm.  The C5a level was expressed as OD492 reading/mg protein. 
Quantification of MCs and MC degranulation.  MCs and MC degranulation in 
skin samples were quantified according to Wershil, et al. (36), with modification. Briefly, 
lesional and nonlesional skin sections of IgG-injected mice were fixed in 10% formalin.  
Paraffin sections (5-μm thick) were prepared and stained with toluidine blue and H&E.  The 
total number of MCs was counted and classified as degranulated (>10% of the granules 
exhibiting fusion or discharge) or normal in five fields under a light microscope as described 
previously.  The results are expressed as percentage of MC degranulation. 
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MC reconstitution.  Kitw/Kitw-v mice were repaired of their MC deficiency 
selectively and locally by the injection of growth factor-dependent bone marrow-derived 
cultured MCs into the skin (15, 37, 38). Briefly, femoral bone marrow cells from WT and 
C5aR-/- mice were maintained in vitro for 4 weeks in RPMI 1640 complete medium (Life 
Technologies, Grant Island, NY) supplemented with 20% WEHI-3-conditioned medium until 
MCs represented >95% of the total cells as determined by toluidine blue staining and flow 
cytometry analysis using antibodies specific for the MC cell surface markers FcεRI, c-Kit, 
and CD13 (37). Murine IgE and rat anti-mouse IgE were purchased from Southern 
Biotechnology Associates (Birmingham, AL). FITC-labeled rat anti-mouse c-Kit and FITC-
labeled rat anti-mouse CD13 were obtained from DB Pharmingen (San Diego, CA).  MCs 
(1x106 in 20 μl of medium) were injected i.d. into the ears of 8 to 10 week old MC-deficient 
mice.  Medium alone (20 μl) was injected i.d. into the ears of MC-/- and MC+/+ mice to 
serve as negative controls. This procedure selectively and locally reconstitutes the dermal 
MC population without systemic effects (38). MC reconstitution was confirmed by staining 
skin sections from MC-injected sites with toluidine blue.  Ten weeks after the adoptive 
transfer of MCs, when the injected MCs were fully matured into functional cutaneous MCs 
(15, 37, 38), both ears of the mice were injected i.d. with pathogenic anti-BP180 IgG (2 
mg/20 μl/site).  24 hours later, ear skin biopsies were obtained and analyzed by H/E, 
toluidine blue staining and MPO enzyme assay as described above. 
In vivo and in vitro inhibition of p38MAPK activation.  For the in vivo inhibitor 
studies, mice were pretreated with 50 μl of the p38MAPK inhibitor SB203580 or inactive 
analog SB202474 (i.d., 10 μg/g body weight).  Two hours later, the mice were injected i.d. 
with 50 μl of pathogenic IgG or control IgG (2.5 mg/g body weight) and the mice were 
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examined at different time points for BP skin lesions and p38MAPK activation (as described 
below). For in vitro inhibitor studies, cultured bone-marrow-derived MCs from C57BL/6J 
mice were incubated with C5a (25 ng/ml) in the presence of p38MAPK inhibitor SB203580 
(20 μM) for 0-60 min and cell extracts were assayed for p38MAPK activation.  
Detection of total and phospho-p38MAPK.  Protein was extracted from skin 
samples in lysis buffer  (8 M urea, 4% 3-(3-cholamidopropyl)dimethylammonio-1-
propanesulfonic acid (CHAPS), 2.5 mM dithiothreitol, 40 mM Tris, 10 µM pepstatin, 100 
µM leupeptin, 10 µM E-64, 1 mM phenylmethylsulfonyl fluoride, 0.1 M sodium 
orthovanadate, 0.5 mM sodium fluoride, and Okadaic acid). For the cell culture studies, bone 
marrow-derived MCs were incubated with buffer control or C5a (25 ng/ml) in the absence or 
presence of SB203580 (20 μM) for 0-60 min at 37° C. The cells were harvested and lysed on 
ice, and 20 µg of each protein extract was loaded on a 10% acrylamide gel and separated by 
SDS-PAGE. Gels were transferred to PVDF (Millipore) membranes and probed by 
immunoblot for total p38MAPK and phospho-p38MAPK. Western blots were developed by 
enhanced chemiluminescence (ECL) reaction (Amersham Biosciences). The signal intensity 
was quantified by scanning chemiluminescence on a GeneGnome scanner (Syngene Bio 
Imaging, Frederick, MD) using GeneSnap software.   
Statistical analysis.  The data are expressed as mean + SEM and were analyzed using 
the Student's paired t-test.  A p value less than 0.05 was considered significant. 
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2.3  RESULTS 
Mice lacking the classical pathway of the complement system are resistant to 
experimental BP and exhibit a reduced level of skin C5a.  We previously reported that the 
classical pathway of complement activation is critical to the pathogenesis of experimental BP 
in mice (18).  Wild-type (C4+/+) mice and mice deficient in the alternative pathway 
component factor B (Fb-/-) developed subepidermal blisters following injection with 
pathogenic anti-mBP180 IgG; however, mice deficient in the classical pathway component 
C4 (C4-/-) were resistant to blister formation (Fig. 2.1A and Table 2.1).  24 hours following 
injection, C4-/- mice had significantly lower levels of C5a present in the skin compared to 
WT and Fb-/- mice (p<0.0001, Fig. 2.1B).  Significantly fewer infiltrating PMNs were 
present in the skin of the C4-/- mice than in the WT or Fb-/- mice, as determined by 
quantification of the PMN cell marker myeloperoxidase (MPO) enzymatic activity (Fig. 
2.1C).  These results demonstrate that complement activation via the classical pathway is 
essential for generation of C5a, recruitment of PMNs to the skin, and blistering in 
experimental BP. 
Mice lacking C5a receptor are resistant to experimental BP and exhibit impairment 
in MC degranulation and p38MAPK activation.  C5a fragments primarily act through 
binding to the C5a receptor (C5aR, or CD88) (39).  Having determined that high levels of 
C5a are present in the skin of mice susceptible to experimental BP, we next examined the 
role of the C5aR in disease development.  We injected C5aR-deficient mice (C5aR-/-) and 
WT mice (C5aR+/+) with pathogenic anti-BP180 antibodies and found that C5aR+/+ mice 
developed blisters, but C5aR-/- mice did not (Figs. 2.2A and Table 2.1). Although C5aR-/- 
mice failed to develop skin lesions, the amount of C5a present in their skin was comparable 
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to the WT mice at 4 h post IgG injection (Fig. 2.2B), when the early phase of PMN 
infiltration begins (17). These data demonstrate that C5aR deficiency does not affect C5a 
generation. However, MC activation in the skin of the pathogenic IgG-injected C5aR-/- mice 
was severely impaired as evidenced by toluidine blue staining, a MC-specific histochemical 
staining.   At 2 h post-injection when MC degranulation triggered by pathogenic IgG reaches 
its peak in experimental BP (15), extensive MC degranulation was observed in the dermis of 
WT mice (Fig. 2.2C, left panel).  In contrast, C5aR-/- mice exhibited a minimal level of MC 
degranulation in the dermis (Fig. 2.2C, right panel). We quantified MC degranulation and 
found a significant reduction in the number of degranulating MCs in C5aR-/- mice compared 
to WT mice (p<0.001, Fig. 2.2D). Because MC degranulation releases cytokines that recruit 
PMNs to the skin during experimental BP pathogenesis (15), we hypothesized that the C5aR-
/- mice would be unable to effectively attract PMNs to the skin.  Indeed, the pathogenic IgG-
injected C5aR-/- mice showed a significantly reduced PMN infiltration in the skin as 
compared to the diseased WT mice (Fig. 2.2E).  
In addition to the lack of MC activation, C5aR-/- mice injected with pathogenic 
antibodies also lacked activation of p38MAPK, a critical signaling pathway in inflammation 
and autoimmunity (28). By immunoblotting, the lesional skin of the pathogenic IgG-injected 
WT mice exhibited a much more intense phosphorylated p38MAPK band as compared to the 
skin of the pathogenic IgG-injected C5aR-/- mice (Fig. 2.3A, lane 2 vs. lane 4).  Quantitative 
analysis of intensity of each band on immunoblots confirmed that the phospho-p38 levels in 
the lesional skin of the C5aR+/+ mice were significantly higher than C5aR-/- mice 
(p<0.0001, Fig. 2.3B, bar 2 vs. bar 4). These results suggest that the molecular interaction 
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between C5a and C5aR leads to MC activation and p38MAPK signaling, followed 
subsequently by PMN recruitment and BP blistering.   
p38MAPK activation is required for experimental BP.  To determine whether 
p38MAPK activation is involved in the disease development or is simply a secondary stress 
response, neonatal WT mice were pretreated with the p38MAPK inhibitor SB203580 or 
inactive control SB202474 (i.d., 10 μg/g body weight). Two hours later, the mice were 
injected i.d. with pathogenic antibodies.  The SB202474-treated mice developed clinical and 
histological subepidermal blisters with IgG deposition at the BMZ (Fig. 2.4A, left panels; 
also Table 2.1). However, SB203580 treatment completely abolished the BP skin lesions 
(Fig. 2.4A, right panels). Mice pretreated with SB202474 exhibited significantly higher 
levels of p38MAPK phosphorylation at 2 and 24 hours post IgG injection (Fig. 2.4B, lanes 2 
and 5) than mice pretreated with SB203580 (Fig. 2.4B, lanes 3 and 6).  Inhibition of 
p38MAPK activation also resulted in significantly reduced MC degranulation (Fig. 2.4C, 
bar 4 vs. bar 3) and PMN infiltration (Fig. 2.4D, bar 4 vs. bar 3). These results demonstrate 
that p38MAPK is critical for MC activation and subsequent the development of experimental 
BP.   
C5aR-mediated p38MAPK activation depends on MCs.  The complement system 
and MC activation are indispensable to the pathogenesis of experimental BP (18, 40).  
Having demonstrated that p38MAPK activation is also required for disease development, we 
next investigated the links between complement, MCs, and p38MAPK.  MCs express C5aR 
and can be activated by C5a (41), so we reasoned that the interaction of C5a with the MC 
C5aR may trigger p38MAPK signaling.  To test this hypothesis, we injected neonatal MC-
sufficient (MC+/+) and MC-deficient (MC-/-) mice with PBS or recombinant C5a (rC5a) 
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(i.d., 50 ng in PBS/mouse) and analyzed phosphorylated p38MAPK levels in the skin at the 
injection sites. We observed a significantly higher level of p38MAPK activation in the rC5a-
treated MC+/+ mice (Fig. 2.5A, lane 2) as compared to the rC5a-treated MC-/- mice (Fig. 
2.5A, lane 4). In vitro, we found that bone marrow-derived MCs, when incubated with rC5a 
(25 ng/ml) for as little as 5 minutes, exhibited high levels of p38MAPK activation (Fig. 
2.5B).  Addition of SB203580 (20 μM) to MC culture prior to rC5a treatment almost 
completely blocked p38MAPK activation (Fig. 2.5C).  These data strongly suggest that 
p38MAPK activation occurs in MCs following exposure to C5a. 
 C5aR is broadly expressed across a number of cell types, and p38MAPK is activated 
in many immune cells in response to extracellular inflammatory signals (42, 43).  To 
strengthen the evidence that MCs are the key cell type that interact with C5a and promote 
development of experimental BP, we reconstituted MC-/- mice with MCs from C5aR-/- 
mice, or MCs from C5aR+/+ mice.  If p38MAPK activation is dependent on the C5aR on 
MCs, then MC-/- mice reconstituted with MCs expressing C5aR should be susceptible to 
experimental BP, but mice reconstituted with C5aR-deficient MCs should be protected from 
experimental BP. To test this hypothesis, we injected the left ears of MC-/- mice with C5aR-
/- MCs  and the right ears of the same MC-/- mice with C5aR+/+ MCs (1x106 cells/site). Ten 
weeks later, both ears of the mice were injected i.d. with pathogenic anti-BP180 IgG (2 
mg/20 μl/site) and examined 24 hour post IgG injection.  Similar numbers of MCs were 
present in the C5aR+/+ MC reconstituted ears and the C5aR-/- MC reconstituted ears. MC-/- 
mice that were not reconstituted with any MCs and mice reconstituted with C5aR-/- MCs 
developed no skin lesions, while MC-/- mice reconstituted with C5aR+/+ MCs showed 
subepidermal blistering (Fig. 2.6A). The number of infiltrating PMNs in the C5aR+/+ MC-
53 
 
reconstituted site was significantly higher than the C5aR-/- MC-reconstituted site (Fig. 2.6B, 
bar 6 vs. bar 5). Pretreatment with p38MAPK inhibitor SB203580 abolished BP skin lesions 
(Fig. 2.6A, 4th panel) and markedly reduced PMN infiltration in the MC-/- mice 
reconstituted with C5aR+/+ MCs (Fig. 2.6B, bar 7).  Taken together, these results 
demonstrate that disease progression is dependent on MCs expressing C5aR and p38MAPK 
activation.  
 
2.4 DISCUSSION 
Activation of the classical pathway of complement generates C5a, a molecule critical for 
tissue inflammation and the recruitment of PMNs to the cutaneous BMZ.  C5a may carry out 
this role either directly (functioning as a PMN chemoattractant itself) or indirectly (by 
stimulating local cells to release proinflammatory mediators such as IL-8), or through a 
combination of these two mechanisms (44). In experimental BP, we found that C5a 
contributes to disease progression primarily through interaction with C5aR on MCs, as 
evidenced by the failure of C5aR-/- mice to induce MC degranulation and subsequent PMN 
accumulation upon passive transfer of pathogenic anti-BP180 antibodies.   
Without C5aR, activation of p38MAPK in the pathogenic anti-mBP180 IgG-injected 
mouse skin is impaired. p38MAPK is an important signaling molecule involved in translating 
extracellular environmental conditions into cellular responses (27, 28). This signaling 
pathway plays a key role in numerous immune and inflammatory diseases, including 
rheumatoid arthritis and skin autoimmune disease pemphigus vulgaris (45-47).  Our data 
show that p38MAPK activation is not a secondary stress response and instead is required for 
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experimental BP, as mice treated with p38MAPK inhibitors are protected from disease 
progression.   
It has been reported that in PMNs and monocytes, interaction of C5a and C5aR leads to 
activation of p38MAPK (24-26). In this study, we provide direct evidence that MCs also use 
the same pathway of C5a-C5aR-mediated p38MAPK activation.  WT mice injected with 
rC5a exhibited significantly greater p38MAPK phosphorylation than MC-/- mice, indicating 
that MCs are a key source of the p38MAPK signaling required for induction of experimental 
BP.  Compellingly, we found that MC-/- mice reconstituted with MCs expressing C5aR prior 
to passive transfer of pathogenic antibody develop blisters; however, mice reconstituted with 
MCs lacking C5aR expression do not exhibit blister formation.  Furthermore, rC5a directly 
activates p38MAPK in C5aR-sufficient but not C5aR-deficient cultured MCs. Taken 
together, these data demonstrate that C5a interaction with C5aR on MCs and the subsequent 
MC p38MAPK activation are indispensable for development of experimental BP.  In 
summary, our present studies identify the C5a-C5aR interaction being a critical molecular 
linker between basal keratinocyte-based complement activation and MC-based p38MAPK 
activation in experimental BP. Activation of p38MAPK is essential for MC activation, PMN 
infiltration, and blister formation in experimental BP.   
Inhibitors of p38MAPK are currently under investigation for treatment of autoimmune 
and inflammatory diseases (48-50).  We found that BP patients have significantly elevated 
levels of p38MAPK activation in lesional skin, indicating that p38MAPK is likely an 
important mediator of inflammation in the human, as well as the mouse.  Thus treatment of 
BP with these p38MAPK inhibitors may prove to be a practical therapy if specific and safe 
inhibitors can be developed. 
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Strain IgG injected Treatment Number of mice Mean disease activity 
Wild-type 
 
 
 
 
C4-/- 
 
 
Fb-/- 
 
 
C5aR-/- 
R50 
R621 
R621 
R621 
 
R50 
R621 
 
R50 
R621 
 
R50 
R621 
- 
- 
+ SB203580 
+ SB202474 
 
- 
- 
 
- 
- 
 
- 
- 
16 
22 
6 
6 
 
8 
8 
 
8 
8 
 
8 
8 
0.00 + 0.00 
2.66 + 0.36 
0.33 + 0.11 
2.75 + 0.17 
 
0.00 + 0.00 
0.19 +0.09 
 
0.00 + 0.00 
2.56 + 0.15 
 
0.00 + 0.00 
0.25 + 0.09 
 
Table 2.1.  Role of C5a receptor and p38 MAPK in experimental BP.  Neonatal wild-
type, C4-/-, factor B (Fb)-/-, and C5aR-/- mice were injected intradermally with either control 
IgG R50 or pathogenic rabbit anti-mBP180 IgG R621 alone (2.5 mg/g body weight) or 
pretreated with the p38MAPK inhibitor SB203580 or inactive control SB202474 (10 μg/g 
body weight). All mice were examined 24 h after IgG injection. The extent of cutaneous 
disease was scored as follows: "(-)", no detectable skin disease; "1+", mild erythematous 
reaction with no evidence of the "epidermal detachment sign” [this sign was elicited by 
gentle friction of the mouse skin which, when positive, produced fine, persistent wrinkling of 
the epidermis]; "2+", intense erythema and "epidermal detachment" sign involving 10-50% 
of the epidermis in localized areas; and "3+", intense erythema with frank "epidermal 
detachment" sign involving more than 50% of the epidermis in the injection site. The clinical 
disease severity is expressed as Mean + SE and analyzed by paired Student t-test.  
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CHAPTER 3 
FUNCTIONAL INTERACTION BETWEEN COMPLEMENT AND THE PRO-
INFLAMMATORY CYTOKINE TNF-α IN EXPERIMENTAL BULLOUS PEMPHGOID  
 
Bullous pemphigoid (BP) is a chronic inflammatory skin blistering disease characterized 
by autoantibodies against two major hemidesmosomal proteins, BP230 and BP180.  Existing 
therapeutic strategies rely heavily on corticosteroids; hence there is urgent need for new 
treatments.  High levels of TNF-α are reported in the sera of BP patients, providing a 
possible intervention target.  However, the role of TNF- α in BP is unknown.  In this study, 
we examined TNF-α’s activity using two IgG passive-transfer mouse models of BP.  One of 
the models is a humanized model, where human anti-BP180 is injected into a knock-in 
mouse which expresses the human pathogenic portion of BP180.  Upon injection with 
pathogenic anti-BP180 antibodies, mice exhibit sharp mast cell (MC)-dependent increases in 
TNF-α in the skin and blister fluid.  Mice lacking TNF-α or MCs fail to recruit sufficient 
numbers of neutrophils to the skin and do not develop blisters.  TNFR1 but not TNFR2 
expression on MCs is required for experimental BP.  Additionally, anti-TNF-α therapies 
abrogated disease pathogenesis.  These data indicate that pathogenic antibodies trigger TNF-
α release from MCs, and that TNF-α mediates neutrophil infiltration and disease by acting in 
an autocrine fashion on MCs.  Additionally, this study provides rationale for considering 
anti-TNF therapy for the treatment of BP. 
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3.1 INTRODUCTION 
Bullous pemphigoid (BP) is a chronic, autoimmune skin blistering disease that 
predominantly occurs in the elderly, but also can affect younger people (1-3).  BP is 
associated with high mortality rates, ranging from 12% and 40% in the first three years after 
diagnosis (4, 5).  The conventional therapy for BP over the past several decades has been 
high-dose, long-term systemic oral corticosteroids and immunosuppressive agents (6).  
However, long term use of corticosteroids is associated with deleterious health effects, 
including severe infection, diabetes mellitus, osteoporosis, hypertension, renal failure, 
lymphoma, and squamous cell carcinoma (7).  The negative side effects of 
immunosuppression therapy may account for a significant portion of the morbidity and 
mortality associated with BP.  Even when disease is successfully treated, up to 45% of 
patients suffer a relapse within six months of cessation of therapy (8), underscoring the 
urgent need for novel therapeutic interventions.   
BP patients develop circulating and tissue bound autoantibodies against two major 
hemidesmosomal proteins, BP230 (BPAG1) and BP180 (BPAG2, type XVII collagen) (9-
14).  These anti-hemidesmosomal autoantibodies, along with complement components, are 
deposited along the basement membrane at the dermal-epidermal junction (DEJ) of 
perilesional skin (15).  Basal keratinocytes detach from the underlying dermis, leading to the 
formation of tense, fluid filled blisters (1). Blister fluid contains cellular dermal inflammatory 
infiltrates, including eosinophils, neutrophils (PMNs), lymphocytes, degranulated mast cells 
(MCs), and monocyte/macrophages (16-21). In addition, various inflammatory mediators that 
can recruit/activate MCs or leukocytes have been identified in lesional skin and/or blister 
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fluids of BP patients, including C5a, eosinophilic/neutrophilic chemotactic factors, 
histamine, leukotrienes, and various cytokines (3, 22-28). 
The cytokine TNF-α is a potent and pleiotropic mediator of biological responses and 
signals through the TNF-α receptors (TNFRs) TNFR1 and TNFR2 (29). TNF-α is implicated 
in the pathogenesis of a number of inflammatory diseases, including rheumatoid arthritis, 
inflammatory bowel disease, psoriasis, and pemphigus vulgaris (30).  Elevated levels of 
TNF-α have been reported in the serum and blister fluid of BP patients, and disease severity 
correlates with TNF-α serum levels (31, 32).  In one case study, BP in a patient with severe 
psoriatic background was successfully treated with a combination therapy of rituximab and 
etanercept (29), while etanercept alone was used to control psoriasis and BP in another 
patient (30).  These studies are limited in scope but provide the attractive possibility of 
utilizing established anti-TNF-α therapies to treat BP patients However, prior to considering 
the broad application of TNF- α therapies to BP, it is vital to understand the role of this 
cytokine in the pathogenesis of BP.   
To address this issue, we used two IgG passive transfer mouse models of BP that mimic 
the key features of human BP to investigate the role of TNF-α in the pathogenesis of 
experimental BP.  In the first of these models, neonatal C57BL/6J mice are injected with 
polyclonal rabbit antibodies that recognize the immunodominant domain of murine BP180, 
called NC14A (33).  NC14A is the murine homolog of NC16A, the domain of human BP180 
that harbors multiple epitopes recognized by human BP autoantibodies (34, 35).  Animals 
injected with rabbit anti-BP180NC14A IgG develop skin blistering that depends on 
complement activation, MC degranulation, and PMN infiltration to the skin (36-38).  In the 
second model, mice “humanized” to express NC16A instead of NC14A are injected with 
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BP180-specific IgG isolated from human BP patients.  The injected patient antibodies trigger 
blistering that also requires complement, MC degranulation, and PMN recruitment (39).  
Using these two mouse models, we describe a key role for TNF-α via TNFRI in the 
pathogenesis of BP. 
 
3.2 EXPERIMENTAL PROCEDURES 
Laboratory animals.  Breeding pairs of C57BL/6J, MC-deficient WBB6F1-
Kitw/Kitw-v (MC-/-), C5a receptor-deficient (C5aR-/-), TNFR1-deficient (TNFR1-/-), TNFR2-
deficient (TNFR2-/-), and TNFR1 and TNFR2 deficient (TNFR1,2-/-) mice were purchased 
from Jackson Laboratories (Bar Harbor, ME) and maintained at the University of North 
Carolina at Chapel Hill.  The MC deficiency in Kitw/Kitw-v mice are caused by distinct 
mutations in MC c-Kit (40).  Humanized NC16A mice were generated as described (39). In 
these mice, the mouse BP180NC14A domain was replaced with human BP180NC16A 
domain. Neonatal mice (24-36 hours old with body weights between 1.4 and 1.6 g) were used 
for passive transfer experiments.  All animal care and animal experiments were approved by 
the UNC Animal Care Committee and were in accordance with the National Institutes of 
Health guidelines. 
Preparation of pathogenic anti-BP180 IgG.  The preparation of recombinant 
murine BP180 (mBP180) and the immunization of New Zealand White rabbits were 
performed as previously described (33, 41, 42). Briefly, New Zealand White rabbits were 
immunized with the GST-hBP180NC16A or GST-mNC14A fusion protein. IgG fractions 
from sera of the immunized rabbits were purified using a protein G Sepharose column 
(Sigma). The pathogenicity of these IgG preparations was tested by passive transfer 
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experiment as described below.  A pathogenic anti-mBP180 IgG preparation (R530) and a 
control IgG preparation were used in this study (38).  For experiments with human patient 
IgG, BP180NC16A-specific autoantibodies from BP patients were purified using a 
BP180NC16A-glutathione Sepharose column (39).  
 
Induction of experimental BP and clinical evaluation of animals.  Neonates were 
given on the back one i.d. injection of a sterile solution of IgG in PBS (50 μl IgG, 2.5 mg 
IgG/g body weight) as described elsewhere (33). The skin at the IgG-injection site of the 
mice from the test and control groups was examined at different time points after the IgG 
injection.  The extent of cutaneous disease was scored as follows: "(-)", no detectable skin 
disease; "1+", mild erythematous reaction with no evidence of the epidermal detachment sign 
[this sign was elicited by gentle friction of the mouse skin which, when positive, produced 
fine, persistent wrinkling of the epidermis]; "2+", intense erythema and epidermal 
detachment sign involving 10-50% of the epidermis in localized areas; and "3+", intense 
erythema with frank epidermal detachment sign involving more than 50% of the epidermis in 
the injection site. 
After clinical examination, the animals were sacrificed, and skin and serum specimens 
were obtained. Skin sections were used for a) routine histological examination by light 
microscopy (H&E staining) to localize the lesional site and PMN infiltration, b) toluidine 
blue staining to quantify MCs and MC degranulation, c) direct IF assays to detect rabbit IgG 
and mouse C3 deposition at the BMZ, and d) myeloperoxidase (MPO) enzymatic assay to 
quantify the PMN accumulation at the skin injection site described below.  The sera of 
injected animals were tested by indirect IF techniques to determine the titers of rabbit anti-
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mBP180 antibodies using mouse skin cryosections as the substrate.  Direct and indirect IF 
studies were performed as previously described (33) using commercially available FITC-
conjugated goat anti-rabbit IgG (Kirkeggard& Perry Laboratories Inc.).  Monospecific goat 
anti-mouse C3 IgG was purchased from Cappel Laboratories. 
 
Pretreatment with TNF-α neutralizing antibodies and rTNF-α.  Neonatal WT and 
TNF-α-deficient (TNF-α-/-) mice were injected i.d. with 50 μl of BSA control (1 μg/50 μl 
PBS ), TNF-α neutralizing antibodies (1 μg/50 μl PBS, R&D System), or rTNF-α (50 ng/50 
μl PBS, R&D System). Two hours later, the mice were given i.d. with pathogenic anti-
mBP180 antibodies and examined 24 h post IgG injection.  
Identification of TNF-α in blister fluid.  One hundred microliters of PBS was injected 
into the skin blisters (formed 12 hours after pathogenic IgG injection) and nonlesional sites, 
and withdrawn 1 minute later. The “washout” PBS was centrifuged at low speed (1,000 g) 
for 5 minutes to remove cells and then at high speed (12,000 g) for 5 minutes to remove cell 
debris. TNF-α in the supernatant was measured by a mouse TNF-α-specific ELISA kit 
(R&D System). TNF-α level were expressed as pg/ml.   
RT-PCR.  mRNA was isolated from skin samples using an RNeasy kit (Qiagen).  TNF-
α, TNFR1, TNFR2 messages were amplified from the cDNA using the following primers:  
Forward:5’-TAGTGGTGCCAGCCGATGGGT-3’ and Reverse:  5’-
GACCTGCCCGGACTCCGCAA-3’ for mouse TNF-α, Forward:   5’- 
GTGCGTCCCTTGCAGCCACT -3’ and reverse 5’-AGGGTCAGCTCCCTGGGTTGG-3’ 
for mouse TNFR1, Forward:   5’- GTTTCAGGAGGCCCGTGCCAG -3’ and Reverse:5’-
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CCATATCCGGCACACCAAGGGGCA -3’ for mouse TNFR2. Sizes of PCR products were 
305, 439, and 293 base pairs for TNF-α, TNFR1, and TNFR2, respectively. 
Quantification of PMN accumulation at the skin site.  Myeloperoxidase (MPO) 
activity in skin sites of the injected animals was assayed as a measure of PMN infiltration as 
described (43, 44).  A standard reference curve was established using purified MPO (Athens 
Research and Technology, Inc., Athens, Georgia).  The skin samples were extracted by 
homogenization in an extraction buffer containing 0.1 M Tris-Cl, pH 7.6, 0.15 M NaCl, 0.5% 
hexadecyltrimethylammonium bromide.   MPO activity in the supernatant fraction was 
measured by the change in optical density at 460 nm resulting from decomposition of H2O2 
in the presence of o-dianisidine.  MPO content was expressed as units of MPO activity/mg 
protein.  Protein concentrations were determined by the Bio-RAD dye-binding assay using 
BSA as a standard. 
Quantification of MCs and MC degranulation.  MCs and MC degranulation in skin 
samples were quantified according to Wershil, et al. (45) with modification. Briefly, lesional 
and nonlesional skin sections of IgG-injected mice were fixed in 10% formalin.  Paraffin 
sections (5-μm thick) were prepared and stained with toluidine blue and H&E.  Toluidine 
blue stains histamine in the MC granules (46).  Total number of MC was counted and 
classified as degranulated (>10% of the granules exhibiting fusion or discharge) or normal in 
five fields under a light microscope as described previously.  The results were expressed as 
percentage of MC degranulating. 
Determination of C5a levels in skin.  Skin from the IgG injection site of the diseased 
and control mice was mechanically homogenized in PBS to extract proteins.  The level of 
mouse C5a (mC5a) in the skin was measured by ELISA (R&D Systems, Minneapolis, MN).  
75 
 
Microtiter plates were coated with a rat anti-mouse C5a antibody, incubated with skin protein 
extracts, followed by goat anti-mC5a detection antibody, and then developed and read at 
OD492nm.  The C5a level was expressed as OD492 reading/mg protein. 
MC reconstitution.  Kitw/Kitw-v mice were repaired of their MC deficiency selectively 
and locally by the injection of growth factor-dependent bone marrow-derived cultured MC 
into the skin (47, 48). Briefly, femoral bone marrow cells from WT and C5aR-/- mice were 
maintained in vitro for 4 wk in RPMI 1640 complete medium (Gibco/Life Technologies, 
Grant Island, NY) supplemented with 20% WEHI-3-conditioned medium until MCs 
represented >95% of the total cells as determined by toluidine blue staining and flow 
cytometry analysis using antibodies specific for MC cell surface markers FcεRI, c-Kit, and 
CD13 (47). Murine IgE and rat anti-mouse IgE were purchased from Southern 
Biotechnology Associates (Birmingham, AL). FITC-labeled rat anti-mouse c-Kit and FITC-
labeled rat anti-mouse CD13 were obtained from BD Biosciences (San Diego, CA).  MCs 
(1x106 in 20 μl of medium) were injected i.d. into right ears of MC-deficient mice.  Medium 
alone (20 μl) were injected i.d. into left ears of the same mice as negative control. This 
procedure selectively and locally reconstitute dermal MC population without systemic effects 
(48). To confirm MC reconstitution, skin sections from MC-injected sites were stained by 
toluidine blue. Ten weeks after adoptive transfer of MCs, both ears of the mice were injected 
i.d. with pathogenic anti-BP180 IgG (2 mg/20 μl/site).  Twenty four hours later, ear skin 
biopsies were obtained and analyzed by H&E, toluidine blue staining and MPO enzyme 
assay as described above. 
Statistical analysis.  The data are expressed as mean + SEM and were analyzed using 
the Student's paired t-test.  A p value less than 0.05 was considered significant. 
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3.3  RESULTS 
Pathogenic anti-BP180 antibodies induce local expression of TNF-α.  As we 
previously reported (33), wild-type (WT) C57BL/6J mice injected with pathogenic rabbit 
anti-mBP180 IgG R530 (2.5 mg/g body weight) develop intense clinical blisters after 24 
hours (Figure 3.1A, top row, arrow denotes blistered area).  A linear pattern of IgG binding 
along the DEJ is detected by direct immunofluorescence (Figure 1A, middle, arrow marks 
DEJ), and separation of the dermis from the epidermis is apparent in H&E stained skin 
sections (Figure 3.1A, bottom).  Mice injected with control IgG lack blisters and antibody 
deposition. Levels of myeloperoxidase (MPO) in the skin are significantly higher in mice 
given R530 than in mice given control IgG, indicating that PMNs are recruited to the skin in 
the pathogenic antibody-injected animals (Figure 3.1B).  To investigate the role of TNF-α in 
experimental BP, we collected skin biopsies from the affected area of R530-injected mice 
and from the equivalent, unblistered areas of control IgG-injected mice and measured TNF-α 
protein, which was significantly higher (over 25 fold) in the blister fluid from the R530 
injected mice than in the wash-out of control IgG injected mice (Figure 3.1C). These results 
demonstrate that expression of TNF-α is greatly augmented in experimental BP.   
TNF-α is required for the development of experimental BP.  Having established 
that TNF-α levels rise dramatically in mice given pathogenic anti-BP180 antibodies, we next 
investigated whether TNF-α is required for experimental BP disease pathogenesis.  TNF-α 
deficient mice (TNF-α-/-) and WT mice were pretreated locally with PBS, recombinant TNF-
α (rTNF-α), or anti-TNF-α neutralizing antibody. Two hours later, the mice were injected 
i.d. with control IgG or R530.  24 hours post IgG injection, TNF-α-/- mice showed no skin 
lesions clinically or histologically (Figure 3.2A, left column). However, pretreatment with 
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rTNF-α restored clinical and histological lesions in TNF-α-/-mice (Figure 3.2A, middle 
column). WT mice pretreated with TNF-α neutralizing antibody were also resistant to 
experimental BP (Figure 3.2A, right column). Taken together, these data demonstrate an 
essential role for TNF-α in experimental BP.  
Experimental BP pathogenesis proceeds through the activation of complement, 
followed by MC degranulation, and then PMN infiltration to the skin (49).  We next 
examined the effect of TNF-α deficiency on each of these processes.  Four hours after IgG 
injection, similar levels of C5a were detected by ELISA in the skin of WT and TNF-α-/- 
animals injected with control IgG or R530 IgG (Figure 3.2B).  Toluidine blue stained skin 
sections from mice sacrificed two hours after R530 antibody injection, when MC 
degranulation reaches its peak level (37), revealed equivalent levels of MC degranulation in 
the dermis of WT and TNF-α-/- animals (Figure 3.2C).  While complement activation and 
MC degranulation were unaffected by the loss of TNF-α, PMN recruitment was significantly 
impacted (Figure 3.2D).  Twenty-four hours after R530 injection, WT mice exhibit a 
significant increase in skin PMN levels.  Pretreatment with the TNF-α neutralizing antibody 
ablated the PMN recruitment in WT mice.  TNF-α-/- animals recruit significantly fewer 
PMNs to the skin than the WT mice, but PMN recruitment was completely restored in TNF-
α-/- animal pretreated with rTNF-α.  These experiments demonstrate that TNF-α is required 
for PMN recruitment in experimental BP. 
MCs are the source of TNF-α needed for experimental BP pathogenesis.  Upon 
degranulation, MCs release large amounts of pre-formed TNF-α (50).  However, a number of 
other skin-resident cell populations can produce TNF-α, including keratinocytes and 
Langerhans cells (8).  To determine if MCs are the critical cellular source of TNF-α in the 
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development of experimental BP, we first examined the kinetics of TNF-α production in the 
skin of WT and WBB6F1-Kitw/Kitw-v mice which lacked MC (referred to as MC-/-) post-
injection with R530 or control IgG.  Mice (n=6 per group) were sacrificed 0, 1, 2, 4, 8, and 
24 hours post IgG injection, and blisters or the area of skin where blisters would form were 
washed with 100 μl of PBS to collect protein.  TNF-α levels were measured in the washout 
fluids by ELISA. Injection with R530 IgG induced an initial peak in TNF-α levels 2 hours 
post injection, and a second peak 24 hours post-injection in WT mice (Figure 3.3).  In 
contrast, TNF-α levels did not significantly increase in mice injected with control IgG at all 
time-points.  The TNF-α protein level peaked 2 h post injection which coincides with the 
peak in MC degranulation, suggesting that MCs release of preformed TNF-α may be the key 
source of the cytokine in the early stages of experimental BP.  To further investigate this 
hypothesis, we tested whether TNF-α was produced in MC-/- mice following R530 injection.  
TNF-α levels in the washouts from MC-/- mice injected with R530 were not significantly 
different from the levels observed in mice injected with control IgG (Figure 3.3, closed 
triangles) indicating that MC is the source of TNF-α in response to R530 injection. 
 MC reconstitution experiments further confirmed that MCs are the critical source of 
TNF-α in experimental BP pathogenesis.  TNF-α-/- mice did not develop blisters following 
injection with pathogenic IgG.  Furthermore, reconstitution with 1x106 MC from TNF-α-/- 
mice prior to R530 injection does not restore histological blistering.  However, TNF-α-/-mice 
reconstituted with WT MCs prior to R530 injection develop histological blistering (Figure 
3.4A).  Similarly, MC-/- mice and MC-/- mice reconstituted with TNF-α-/- MCs fail to develop 
blisters following R530 injection, but MC-/- mice reconstituted with WT MCs develop 
blisters (Figure 3.4B).  Only mice with WT MCs, but not TNF-α-/- MCs are able to recruit 
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PMNs to the skin and develop blisters following injection with pathogenic antibodies 
(Figure 3.4C).   Taken together, these data demonstrate that TNF-α released by 
degranulating MCs is required for experimental BP.   
C5a-C5a receptor interaction is required for TNF-α release.  We recently reported 
that C5a interaction with the C5a receptor (C5aR, or CD88) on MCs triggers activation of 
p38MAPK in MCs and MC degranulation (51).  To assess if TNF-α released by 
degranulating MCs is also affected by the C5a pathway, we injected WT and C5aR-/- 
neonatal mice with R530 and examined various stages of disease progression.  C5aR-/- mice 
fail to develop clinical blisters after 24 hours (Figure 3.5A), despite generating levels of C5a 
equivalent to the WT mice (Figure 3.5B).  MC degranulation is significantly impaired in the 
C5aR-/- mice injected with R530 compared to WT mice injected with R530, and washout 
fluid from C5aR-/- mice contains significantly lower levels of TNF-α than washout from 
diseased WT mice (Figures 3.5C, 3.5D).  C5aR-/- mice fail to recruit PMNs to the skin 
following R530 injection, and reconstitution with C5aR-/- MCs or TNF-α-/- MCs does not 
restore PMNs.  Only reconstitution with WT MCs restores PMN infiltration to the skin 
(Figure 3.5E). These experiments place C5a upstream of TNF-α production and PMN 
recruitment to the skin.   
TNF-α receptor 1 mediates the downstream effects of TNF-α.   TNF-α acts via 
TNFR1 and TNFR2.  To determine which TNF receptors are required for experimental BP 
pathogenesis, we first looked at receptor expression following pathogenic antibody injection.  
Over 8 hours post injection, TNFR1 is expressed constitutively, whereas TNFR2 mRNA 
expression increased over time (Figure 3.6A).  We next injected TNFR1-/-, TNFR2-/-, and 
TNFR1,2-/- mice with R530 and checked for clinical blistering after 24 hours.  TNFR2-/- mice 
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developed extensive blisters equivalent to those seen on WT mice, but the TNFR1-/- and 
TNFR1,2-/- were protected from disease (Figure 3.6B).    We found that PMN infiltration is 
impaired in both TNFR1-/- and TNFR1,2-/- mice, indicating that TNFR1 is required for the 
transition from MC degranulation to PMN recruitment (Figure 3.6C). 
TNFR1 is broadly expressed across cell types, including MCs, keratinocytes, 
fibroblasts, endothelial cells, and PMNs (52).  To investigate the possibility that TNF-α acts 
on MCs in an autocrine fashion, we performed a series of MC reconstitution experiments.  
TNFR1,2-/- and MC-/- mice were reconstituted with MCs from TNFR1,2-/-, TNFR1-/-, TNFR2-
/-, or WT and then injected with R530 IgG.  The TNFR1,2-/- and the MC-/- mice recruited 
PMNs to the skin and developed BP blisters only when they were reconstituted with TNFR2-
/- or WT MCs (Figure 3.7).  These data indicate that TNF-α acts on TNFR1 expressed by 
MCs in an autocrine fashion to promote experimental BP.  
Human BP patient IgG induces TNF-α production in humanized mouse model.  
To extend these findings to the human BP disease, we used a humanized animal model of 
experimental BP (39).  The humanized mice, called NC16A+/+, express the human sequence 
of the pathogenic portion of BP180 in place of the murine homolog. In these mice, passive 
transfer of anti-BP180NC16A autoantibodies purified from human patients triggers 
experimental BP.  Similar to the rabbit anti-mouse IgG model, disease development depends 
on complement activation, MC degranulation and PMN infiltration (39).  To test whether 
human BP autoantibody-induced skin disease also depends on TNF-α, we injected human 
control IgG or NC16A-specific IgG into NC16A+/+ mice.  The anti-NC16A antibodies 
induced clinical blisters in NC16A mice, and these blisters were prevented by pretreatment 
with anti-TNF-α neutralizing antibodies (Figure 3.8A).  Significantly higher levels of TNF-α 
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were present in blister washout of the humanized mice given pathogenic antibodies as 
compared to the humanized mice injected with human control IgG (Figure 3.8B).  
Pretreatment with anti-TNF-α reduced the total amount of TNF-α present in the washout 
fluid of the anti-NC16A-injected animals. As expected, increased PMN recruitment was 
associated with higher levels of TNF-α in the diseased NC16+/+ mice, and blocked by anti-
TNF-α neutralizing antibodies (Figure 3.8C). These results suggest that TNF-α also acts to 
increase skin blistering and granulocyte infiltration in a humanized model of BP.   
 
3.4  DISCUSSION 
TNF-α is a pleiotropic cytokine with a broad range of biological effects in regulating 
cell growth and death, development, oncogenesis, immune function and the inflammatory 
response (53). Various TNF-α inhibitors are used in the clinic to treat Crohns’ disease, colitis 
and rheumatoid arthritis.  Here, we show evidence for TNF-α’s autocrine effect on MCs in 
experimental BP.  We found that TNF-α is required for development of experimental BP.  
Mice injected with anti-BP180 antibodies develop a significant increase in serum levels of 
TNF-α, and TNF-α is detected in the blister fluid from diseased animals.  Upon injection 
with pathogenic antibodies, animals lacking TNF-α fail to recruit PMNs to the skin and are 
protected from blister formation, but exhibit normal levels of complement activation and MC 
degranulation.  Mice lacking MCs do not exhibit increased serum TNF-α levels upon 
pathogenic antibody injection and are resistant to experimental BP.  Reconstitution with 
TNF-α sufficient MCs restores disease susceptibility in TNF-α-/- or MC-/- mice, whereas 
TNF-α-/- MCs do not.  Activation of the C5aR on MCs by C5a is required for TNF-α release.  
We also found that TNF-α acts on MCs in an autocrine fashion through TNFR1.  MC-/- mice 
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develop experimental BP only when they are reconstituted with MCs that express TNFR1.  
Thus, we conclude that MCs are both the critical source of TNF-α and the key target of TNF-
α in experimental BP.   
 The binding of C5a to C5aR on MCs leads to activation of the p38MAPK signaling 
pathway and MC degranulation (51), which releases preformed TNF-α from intracellular 
stores (Figure 3.9).  This initial wave of TNF-α binds to MC TNFR1 and initiates an 
intracellular signaling cascade that leads to activation of the transcription factors NF-kB and 
c-Jun (54).  NF-kB and c-Jun mediate production of pro-inflammatory factors, and our 
laboratory is currently investigating roles for these compounds in PMN recruitment and BP 
pathogenesis. 
While TNF-α-TNF-R1 interaction on MCs is critical for disease pathogenesis, it is 
possible that TNF-α has other secondary effects during disease.  TNF-α expression in the 
skin upregulates expression of VCAM-1, ICAM-1, and E-selectin, which promotes 
extravasation of inflammatory cells to the skin (55-57).  PMNs and macrophages also express 
high levels of TNFR1; the effects of TNF-α on these cell types remains to be investigated.  
TNF-α also upregulates MC production of matrix metalloproteinase-9 (MMP-9) (58), an 
enzyme critical for the secondary wave of PMN recruitment in experimental BP (59).  While 
PMNs are the key source of MMP-9 in experimental BP, TNF-α stimulated MCs may 
augment these levels.   
Anti-TNF-α therapies, including anti-TNF-α antibodies and TNF-α blocking 
peptidesetanercept (Enbrel), infliximab (Remicade), and adalimumab (Humira), are effective 
in treating a number of inflammatory diseases (30).  Limited case reports indicate that 
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treatment with anti-TNF-α therapies is therapeutically beneficial to BP patients (60, 61).  Our 
work makes a strong case for expansion of anti-TNF-α therapies for the treatment of BP. 
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CHAPTER 4 
DISCUSSION 
 
4.1 INTRODUCTION 
 MCs are dynamic mediators of host defense and tissue homeostasis.  As is often the 
case in the immune system, the versatile means of activation and powerful responses that 
make MCs excellent protectors against microbial invaders also make MCs potent arbiters of 
inflammatory dysfunction and autoimmunity.  Understanding the precise mechanisms that 
lead to initial MC activation and the continuation of MC signaling provides opportunities to 
intervene pharmacologically to curb autoimmunity. 
MCs are key players in the immunopathophysiology of BP.  Intact and degranulated 
MCs are commonly observed in the dermis of BP patients, and histamine and other MC-
derived factors are present in high concentrations in the affected skin (1-4).  Mice injected 
with pathogenic anti-mBP180 antibodies exhibit extensive MC degranulation in the lesional 
skin, similar to that observed in human BP (3, 5).  Importantly, mice lacking MCs do not 
develop experimental BP, indicating that MCs are required for disease development and are 
not merely uninvolved or tangentially involved bystanders activated by local inflammation.  
The critical role of MCs in experimental BP is to recruit PMNs from the circulation to 
migrate into the skin at the site of inflammation (5).  MC degranulation releases a host of 
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chemoactive compounds capable of acting on local endothelial cells to promote PMN capture 
and extravasation (6, 7).  
Activation of the classical pathway of the complement system and generation of the 
anaphylatoxin C5a is required for MC activation in experimental BP (8).  MCs constitutively 
express C5a on their surface, making C5a-C5aR interaction the likely mechanism of MC 
activation.  However, C5aR is broadly expressed on a wide range of tissues, so it is possible 
that C5a acts on another local cell type, such as keratinocytes or Langerhans cells (9, 10).   
TNF-α, along with a number of other cytokines, is released from degranulated MCs 
following FcεR crosslinking, FcγR crosslinking, or C5aR ligation (11).  A potent and 
pleiotropic molecule, TNF-α elicits a huge range of cellular effects, from the triggering of 
apoptosis to the upregulation of proinflammatory cytokines (12).  TNF-α released from 
dermal MCs in experimental BP likely acts on cells in the surrounding microenvironment, 
but the proximity of the MCs to the microvasculature of the DEJ also makes it possible for 
TNF-α to act globally (13).  MC-derived TNF-α could act on the local endothelial cells to 
promote PMN recruitment, or could potentially act on circulating PMNs themselves, as 
PMNs express high levels of TNFR1.  Alternatively, TNF-α  may regulate BP via its action 
on KCs, LCs, or dermal fibroblasts.   
The primary objective of this dissertation was to elucidate the cellular events that 
occur immediately upstream and downstream of MC degranulation in experimental BP.  Our 
central hypothesis is that complement components activate MCs, and proinflammatory 
compounds released from the MCs drive pathology and blistering.  We found that MCs are 
activated by the binding of C5a to C5aR.  C5a-C5aR interaction leads to activation of 
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p38MAPK and MC degranulation.  MC degranulation releases TNF-α, and TNF-α acts in an 
autocrine manner on MC TNFR1 to promote disease development.   
 
4.2 FINDINGS AND IMPLICATIONS 
We found that C5a contributes to experimental BP disease progression primarily through 
interaction with C5aR on MCs.  C5aR-/- mice injected with pathogenic anti-BP180 
antibodies fail to induce MC degranulation and subsequent PMN accumulation.  As 
discussed, C5aR is broadly expressed, so we performed MC reconstitution experiments to 
confirm that the C5aR on MCs and not another cell type that links complement activation 
and MC activation.  Mice lacking all MCs due to a mutation in c-Kit were reconstituted with 
either WT MCs or C5aR-/- MCs prior to anti-BP180 antibody injection.  Only the WT MCs 
restored susceptibility to disease, indicating that if C5aR on MCs directly binds C5a and 
induces MC degranulation.   
The basic signaling mechanism of C5aR is that of a GPCR, where ligation of the 
extracellular terminus induces G protein-mediated activation of secondary messengers within 
the cell (14).  In the case of C5aR, we found that C5a-C5aR interaction results in activation 
of p38MAPK, and that the p38MAPK signaling cascade is required for MC degranulation.   
p38MAPK is significantly less phosphorylated in C5aR-/- mice than WT mice following 
anti-BP180 injection, indicating that C5a binding is the initiating event in the signaling 
cascade.  WT mice injected with rC5a exhibited significantly greater p38MAPK 
phosphorylation than MC-/- mice, indicating that MCs are the key site of p38MAPK 
signaling in experimental BP.  Furthermore, rC5a directly activates p38MAPK in C5aR-
sufficient but not C5aR-deficient cultured MCs. Taken together, these data demonstrate that 
103 
 
C5a interaction with C5aR on MCs and the subsequent MC p38MAPK activation are 
indispensable for development of experimental BP.  In summary, our present studies identify 
the C5a-C5aR interaction being a critical molecular linker between basal keratinocyte-based 
complement activation and MC-based p38MAPK activation in experimental BP. Activation 
of p38MAPK is essential for MC activation, PMN infiltration, and blister formation in 
experimental BP.   
Having established how MCs are activated in experimental BP, we next looked at the 
consequences of MC activation.  We chose to focus on TNF-α based on BP patient data 
demonstrating that elevated levels of TNF-α are present in serum and blister fluid, and 
disease severity correlates with TNF-α serum levels (15, 16).  
 We found that anti-BP180 antibodies triggered release of TNF-α into the serum and 
blister fluid of diseased mice.  The TNF-α is MC-derived, and MC-/- mice do not exhibit 
TNF-α increases.  Mice that lack either TNF-α or MCs fail to recruit sufficient numbers of 
PMNs to the skin to mediate blistering.  MC-/- mice reconstituted with WT MCs are once 
again susceptible to disease, but reconstitution with TNF-α-/- MCs does not restore 
blistering.  These MC reconstitution studies strongly demonstrate that MC-derived TNF-α-/- 
is required for experimental BP.   TNF-α deficient mice are able to activate complement and 
degranulate MCs normally, indicating that the C5a-C5aR mediated activation of MCs is not 
impaired in in the absence of TNF-α.  We also noted that C5aR-/- mice do not experience 
MC degranulation or TNF-α, in keeping with our proposed mechanism of MC activation.   
We next asked what key targets of MC-derived TNF-α are involved in disease 
progression.  Cytokines are at their highest concentration at the site of release, so we looked 
the most local of all environments, the MC itself.  We found that MC-/- mice do not develop 
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disease susceptibility upon reconstitution with TNFR1-/-.  Disease susceptibility is restored 
by reconstitution with TNFR2-/- or WT MCs.  We conclude that the autocrine feedback of 
MC-derived TNFR1-/- on MC themselves is required for experimental BP.  Thus, MCs are 
both the critical source of TNF-α and the key target of TNF- α.   
We propose a revised model for the signaling activity of MCs in BP (Figure 3.9).  
The binding of C5a to C5aR on MCs leads to activation of the p38MAPK signaling pathway 
and MC degranulation, which releases preformed TNF-α from intracellular stores.  Released 
TNF-α binds to MC TNFR1 and initiates an intracellular signaling cascade that leads to 
production of pro-inflammatory factors that recruit PMNs to the skin. 
The studies detailed in this dissertation focused on three molecules that are targets for 
FDA-approved drugs.  Anti-TNF-α therapies include both anti-TNF-α antibodies and TNF-α 
blocking peptides.  Etanercept (Enbrel), infliximab (Remicade), and adalimumab (Humira), 
are effective in treating a number of inflammatory diseases (17).  Limited case reports 
indicate that treatment with anti-TNF-α therapies is therapeutically beneficial to BP patients 
(18, 19).  Our work makes a strong case for expansion of anti-TNF-α therapies for the 
treatment of BP.  Inhibitors of p38MAPK have been investigated for treatment of 
autoimmune and inflammatory diseases (20-22).  Based on our findings that p38MAPK 
modulates MC degranulation and experimental BP pathogenesis, human BP may be 
effectively treated with these inhibitors.  However, p38MAKP inhibitors are associated with 
negative side effects due to numerous off-target responses (23), Efforts to generate more 
specific inhibitors are constantly underway, however, the results of randomized control trials 
are mixed (24, 25).  Eculizumab is a humanized monoclonal antibody that prevents cleavage 
of C5 into C5a and C5b, thus curbing their activities (26). Eculizumab has proven to be very 
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effective in treatment of paroxysmal nocturnal hemoglobinuria, a complement-mediated 
blood pathology (27).  Side effects are generally mild, but depletion of complement increases 
susceptibility to encapsulated organisms such as Neisseria meningitides (28).  Bacterial 
infections are particularly dangerous for patients with impaired skin barrier function,  and BP 
patients often have large areas of eroded skin. 
Special considerations should be made when evaluating the appropriateness of a clinical 
intervention in BP.  Because elderly patients often have multiple co-morbidities associated 
with advanced age, physicians must cautiously consider the likelihood of a drug being 
tolerated.  BP affects the skin, making topical application of medications a possibility. The 
advantage of potentially lower morbidity due to local rather than systemic application must 
be counterbalanced by mobility constraints that affect many BP patients.  In the case of 
p38MAPK inhibitors, several topical treatments have been tested in the laboratory setting, 
but no clinical trial data is available yet (29).   
All three types of drugs described here have the distinct disadvantage of being extremely 
costly compared with corticosteroids.  These drugs would likely be considered last resorts 
rather than first-line efforts at disease management.   
 
4.3  REMAINING QUESTIONS AND FUTURE DIRECTIONS 
 The data described here present an intriguing new look at the signaling events 
associated with MC activation, function, and the potential for crosstalk between pathways.  
The binding of C5a to C5aR on MCs activates the p38MAPK signaling pathway and MC 
degranulation, which releases preformed TNF-α from intracellular stores  (30).   This initial 
wave of TNF-α feeds back to MC TNFR1 and likely initiates an intracellular signaling 
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cascade that leads to activation of the transcription factors NF-kB and c-Jun, though we have 
not yet demonstrated this. (12).  NF-kB and c-Jun mediate production of pro-inflammatory 
factors, and our laboratory is currently investigating roles for these compounds in PMN 
recruitment and BP pathogenesis.   Cross talk between the NF-kB and c-Jun NH(2)-terminal 
kinase (JNK) signaling pathways following TNF-R1 stimulation is an active area of research 
(31).  The genes growth arrest and DNA damage-inducing protein (GADD45β) and X-
chromosome-linked IAP (XIAP) are induced by NF-kB after TNF-R1 engagement and have 
been demonstrated to block JNK activation (32, 33).  GADD45β activates MTK1/MEKK4, 
which in turn activates the p38MAPK and JNK pathways (34).  The question of whether 
cross talk exists between the TNF-R1 signaling and the C5aR signaling via is of great interest 
to the field of MC signal transduction in autoimmunity and has yet to be explored. 
 The relative contribution of TNFR1 and C5aR signaling to the MC cytokines released 
is also an interesting question.  In the animal model, C5aR signaling releases a large bolus of 
proinflammatory mediators by causing degranulation, while TNFR1 signaling conceivably 
activates de novo synthesis of inflammatory factors. It seems unlikely that the TNFR1-
mediated protein synthesis raises local concentrations of cytokines significantly in the short 
frame of time between MC degranulation (4 hours post-antibody injection) and PMN 
recruitment (8 hours post-antibody injection).  Do the MCs produce factor(s) not stored in 
secretory granules upon TNFR1 engagement?  If so, what is the identity of the factor(s)?   
Are these factor(s) directly responsible for PMN recruitment? 
 Like all animal models, experimental BP has limitations.  While the pathogenic 
events of experimental BP occur within 24 hours, human BP is a chronic condition that can 
last years, and relapses are common (35).  In human BP, is C5a consistently available to 
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mediate MC degranulation, or are skin complement levels depleted, forcing MCs to release 
cytokines via signaling cascades other than the C5aR pathway? 
 MC-deficient WBB6F1-Kitw/Kitw-v mice have been used to study the role of MCs in 
physiological processes for many years.  Kitw/Kitw-v mice have mutations in the Kit gene, 
leading to MC deficiency.  However, Kit is involved in development of other cell lineages, so 
Kitw/Kitw-v mice are also deficient in erythrocytes, PMNs, melanocytes, germ cells, 
pacemaker cells, and certain subpopulations of intraepithelial T cells (36).  Recently two 
strains of mice were developed that delete MCs by Cre-lox technology but have intact Kit 
expression (37, 38).  Intriguingly, MC-deficient mice with intact Kit are resistant to 
experimental autoimmune encephalitis and autoimmune inflammatory arthritis (38), in 
contrast to the data obtained with Kitw/Kitw-v animals.  In light of this study, it may be 
pertinent to reexamine the roles of MCs and PMNs in experimental BP using the new MC 
deficient animal strains. 
4.4  CONCLUDING REMARKS 
 Despite being described over 100 years ago, there is still much to learn about the 
actions of MCs under homeostatic and pathologic conditions.  The findings described here 
provide a small sliver of insight into the complex network of interactions between MCs and 
other immune and non-immune cells.    In experimental BP, MCs are activated by the 
binding of C5a to C5aR.  C5a-C5aR interaction leads to activation of p38MAPK and MC 
degranulation.  MC degranulation releases TNF-α, and TNF-α acts in an autocrine manner on 
MC TNFR1 to promote disease development.  We hope that these findings may one day lead 
to alleviation of suffering from BP.  
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